Neurotoxic	O
kynurenine	O
metabolism	O
is	O
increased	O
in	O
the	O
dorsal	O
hippocampus	O
and	O
drives	O
distinct	O
depressive	O
behaviors	O
during	O
inflammation	O

The	O
kynurenine	O
pathway	O
of	O
tryptophan	O
metabolism	O
has	O
an	O
important	O
role	O
in	O
mediating	O
the	O
behavioral	O
effects	O
of	O
inflammation	O
,	O
which	O
has	O
implications	O
in	O
understanding	O
neuropsychiatric	O
comorbidity	O
and	O
for	O
the	O
development	O
of	O
novel	O
therapies	O
.	O

Inhibition	O
of	O
the	O
rate	O
-	O
limiting	O
enzyme	O
,	O
indoleamine	B-GP
2	I-GP
,	I-GP
3	I-GP
-	I-GP
dioxygenase	I-GP
(	O
IDO	B-GP
),	O
prevents	O
the	O
development	O
of	O
many	O
of	O
these	O
inflammation	O
-	O
induced	O
preclinical	O
behaviors	O
.	O

However	O
,	O
dysregulation	O
in	O
the	O
balance	O
of	O
downstream	O
metabolism	O
,	O
where	O
neuroactive	O
kynurenines	O
are	O
generated	O
,	O
is	O
hypothesized	O
to	O
be	O
a	O
functionally	O
important	O
pathogenic	O
feature	O
of	O
inflammation	O
-	O
induced	O
depression	B-DS
.	O

Here	O
we	O
utilized	O
two	O
novel	O
transgenic	O
mouse	B-OG
strains	O
to	O
directly	O
test	O
the	O
hypothesis	O
that	O
neurotoxic	O
kynurenine	O
metabolism	O
causes	O
depressive	O
-	O
like	O
behavior	O
following	O
peripheral	O
immune	O
activation	O
.	O

Wild	O
-	O
type	O
(	O
WT	O
)	O
or	O
kynurenine	B-GP
3	I-GP
-	I-GP
monooxygenase	I-GP
(	O
KMO	B-GP
)-	O
deficient	O
(	O
KMO	B-GP
−/−)	O
mice	B-OG
were	O
administered	O
either	O
lipopolysaccharide	O
(	O
LPS	O
,	O
0	O
.	O
5	O
mg	O
kg	O
−	O
1	O
)	O
or	O
saline	O
intraperitoneally	O
.	O

Depressive	O
-	O
like	O
behavior	O
was	O
measured	O
across	O
multiple	O
domains	O
24	O
h	O
after	O
immune	O
challenge	O
.	O

LPS	O
precipitated	O
a	O
robust	O
depressive	O
-	O
like	O
phenotype	O
,	O
but	O
KMO	B-GP
−/−	O
mice	B-OG
were	O
specifically	O
protected	O
from	O
LPS	O
-	O
induced	O
immobility	O
in	O
the	O
tail	O
suspension	O
test	O
(	O
TST	O
)	O
and	O
reduced	O
spontaneous	O
alternations	O
in	O
the	O
Y	O
-	O
maze	O
.	O

Direct	O
administration	O
of	O
3	O
-	O
hydroxykynurenine	O
,	O
the	O
metabolic	O
product	O
of	O
KMO	B-GP
,	O
caused	O
a	O
dose	O
-	O
dependent	O
increase	O
in	O
depressive	O
-	O
like	O
behaviors	O
.	O

Mice	B-OG
with	O
targeted	O
deletion	O
of	O
3	B-GP
-	I-GP
hydroxyanthranilic	I-GP
acid	I-GP
dioxygenase	I-GP
(	O
HAAO	B-GP
),	O
the	O
enzyme	O
that	O
generates	O
quinolinic	O
acid	O
,	O
were	O
similarly	O
challenged	O
with	O
LPS	O
.	O

Similar	O
to	O
KMO	B-GP
−/−	O
mice	B-OG
,	O
LPS	O
failed	O
to	O
increase	O
immobility	O
during	O
the	O
TST	O
.	O

Whereas	O
kynurenine	O
metabolism	O
was	O
generally	O
increased	O
in	O
behaviorally	O
salient	O
brain	O
regions	O
,	O
a	O
distinct	O
shift	O
toward	O
KMO	B-GP
-	O
dependent	O
kynurenine	O
metabolism	O
occurred	O
in	O
the	O
dorsal	O
hippocampus	O
in	O
response	O
to	O
LPS	O
.	O

Together	O
,	O
these	O
results	O
demonstrate	O
that	O
KMO	B-GP
is	O
a	O
pivotal	O
mediator	O
of	O
hippocampal	O
-	O
dependent	O
depressive	O
-	O
like	O
behaviors	O
induced	O
by	O
peripheral	O
LPS	O
challenge	O
.	O

Introduction	O

Although	O
it	O
remains	O
a	O
major	O
health	O
burden	O
worldwide	O
,	O
the	O
etiology	O
of	O
depression	B-DS
remains	O
unclear	O
.	O

Recent	O
studies	O
indicate	O
that	O
pro	B-GP
-	I-GP
inflammatory	I-GP
cytokines	I-GP
may	O
contribute	O
to	O
the	O
development	O
of	O
depression	B-DS
,	O
1	O
particularly	O
as	O
a	O
comorbidity	O
.	O

Patients	O
undergoing	O
cytokine	B-GP
immunotherapy2	O
or	O
healthy	O
volunteers	O
who	O
receive	O
immune	O
activating	O
agents	O
,	O
such	O
as	O
endotoxin3	O
,	O
4	O
or	O
vaccines5	O
,	O
6	O
in	O
an	O
experimental	O
setting	O
,	O
report	O
developing	O
depression	B-DS
symptoms	O
spanning	O
multiple	O
dimensions	O
(	O
for	O
example	O
,	O
mood	O
,	O
anhedonia	B-DS
,	O
cognition	O
,	O
neurovegetative	O
and	O
anxiety	B-DS
).	O

The	O
time	O
course	O
and	O
severity	O
of	O
these	O
symptoms	O
are	O
positively	O
correlated	O
with	O
pro	O
-	O
inflammatory	O
cytokine	B-GP
levels	O
.	O
4	O
,	O
5	O
Consistent	O
with	O
these	O
clinical	O
observations	O
,	O
peripheral	O
immune	O
activation	O
in	O
rodent	B-OG
models	O
precipitates	O
pro	O
-	O
inflammatory	O
cytokine	B-GP
-	O
dependent7	O
,	O
8	O
,	O
9	O
depressive	O
-	O
and	O
anxiety	B-DS
-	O
like	O
behaviors	O
.	O

Peripheral	O
pro	B-GP
-	I-GP
inflammatory	I-GP
cytokines	I-GP
signal	O
to	O
the	O
brain	O
via	O
multiple	O
routes10	O
and	O
activate	O
the	O
resident	O
immune	O
cells	O
of	O
the	O
brain	O
,	O
microglia	O
.	O

Activated	O
microglia	O
,	O
in	O
turn	O
,	O
secrete	O
cytokines	B-GP
and	O
chemokines	B-GP
,	O
generate	O
oxidative	O
stress	O
molecules	O
and	O
alter	O
local	O
metabolic	O
processes	O
.	O
11	O
Disruption	O
in	O
the	O
balance	O
of	O
tryptophan	O
metabolism	O
along	O
the	O
kynurenine	O
pathway	O
is	O
a	O
putative	O
mechanism	O
linking	O
inflammation	O
,	O
microglia	O
and	O
depression	B-DS
.	O

The	O
rate	O
-	O
limiting	O
enzyme	O
that	O
metabolizes	O
tryptophan	O
to	O
kynurenine	O
,	O
indoleamine	B-GP
2	I-GP
,	I-GP
3	I-GP
-	I-GP
dioxygenase	I-GP
(	O
IDO	B-GP
,	O
Figure	O
1	O
),	O
is	O
potently	O
upregulated	O
by	O
pro	B-GP
-	I-GP
inflammatory	I-GP
cytokines	I-GP
.	O
12	O
Inflammation	O
-	O
associated	O
depression	B-DS
scores	O
in	O
human	B-OG
patients	O
are	O
associated	O
with	O
an	O
elevated	O
kynurenine	O
/	O
tryptophan	O
ratio	O
,	O
an	O
indicator	O
of	O
IDO	B-GP
activity	O
,	O
13	O
and	O
numerous	O
preclinical	O
mouse	B-OG
models	O
have	O
established	O
IDO	B-GP
-	O
dependent	O
kynurenine	O
metabolism	O
as	O
an	O
important	O
mediator	O
of	O
inflammation	O
-	O
induced	O
depressive	O
-	O
like	O
behaviors	O
.	O
14	O
,	O
15	O
,	O
16	O
,	O
17	O
,	O
18	O
Interestingly	O
,	O
microglia	O
are	O
the	O
predominant	O
cells	O
expressing	O
the	O
enzyme	O
(	O
kynurenine	B-GP
3	I-GP
-	I-GP
monooxygenase	I-GP
,	O
KMO	B-GP
,	O
Figure	O
1	O
)	O
for	O
the	O
generation	O
of	O
neurotoxic	O
kynurenine	O
metabolites	O
,	O
and	O
reports	O
in	O
both	O
human19	B-OG
and	O
in	O
mice20	O
have	O
implicated	O
microglial	O
-	O
derived21	O
,	O
22	O
downstream	O
neurotoxic	O
kynurenine	O
metabolites	O
in	O
the	O
pathogenesis	O
of	O
inflammation	O
-	O
associated	O
depression	B-DS
;	O
however	O
,	O
mechanistic	O
studies	O
are	O
yet	O
to	O
be	O
performed	O
.	O

Kynurenine	O
metabolism	O
in	O
the	O
brain	O
results	O
in	O
accumulation	O
of	O
two	O
major	O
neuroactive	O
end	O
products	O
,	O
kynurenic	O
acid	O
(	O
KA	O
)	O
and	O
quinolinic	O
acid	O
(	O
QA	O
;	O
Figure	O
1	O
).	O

Under	O
basal	O
conditions	O
,	O
most	O
kynurenine	O
is	O
metabolized	O
by	O
astrocytes	O
to	O
KA	O
,	O
an	O
N	O
-	O
methyl	O
-	O
D	O
-	O
aspartate	O
(	O
NMDA	O
)	O
and	O
α7	B-GP
-	I-GP
nicotinic	I-GP
acetylcholine	I-GP
receptor	I-GP
antagonist	O
.	O
23	O
,	O
24	O
However	O
,	O
inflammation	O
and	O
subsequent	O
microglial	O
activation	O
is	O
reported	O
to	O
shift	O
kynurenine	O
metabolism	O
toward	O
KMO	B-GP
-	O
dependent	O
production	O
of	O
QA	O
.	O
20	O
,	O
25	O
QA	O
,	O
an	O
NMDAR	B-GP
agonist	O
,	O
can	O
be	O
particularly	O
disruptive	O
to	O
the	O
neuronal	O
environment	O
at	O
higher	O
concentrations	O
,	O
not	O
only	O
by	O
elevating	O
the	O
potential	O
for	O
glutamate	O
excitotoxicty	O
but	O
also	O
by	O
precipitating	O
oxidative	O
damage26	O
and	O
potentiating	O
pro	O
-	O
inflammation	O
.	O

A	O
neurotoxic	O
shift	O
in	O
kynurenine	O
metabolism	O
favoring	O
the	O
production	O
of	O
KMO	B-GP
-	O
dependent	O
metabolites	O
is	O
hypothesized	O
to	O
mediate	O
inflammation	O
-	O
associated	O
behavior	O
changes	O
.	O
27	O
Increased	O
levels	O
of	O
cerebrospinal	O
fluid	O
(	O
CSF	O
)	O
QA	O
in	O
patients	O
undergoing	O
interferon	B-GP
-	I-GP
α	I-GP
immunotherapy	O
were	O
positively	O
correlated	O
to	O
more	O
severe	B-DS
depression	I-DS
scores	O
.	O
19	O
A	O
similar	O
elevation	O
in	O
central	O
QA	O
and	O
its	O
neurotoxic	O
precursor	O
,	O
3	O
-	O
hydroxykynurenine	O
(	O
3	O
-	O
HK	O
),	O
was	O
measured	O
in	O
mice	B-OG
injected	O
peripherally	O
with	O
lipopolysaccharide	O
(	O
LPS	O
).	O

Importantly	O
,	O
LPS	O
-	O
challenged	O
mice	B-OG
also	O
exhibit	O
depressive	O
-	O
and	O
anxiety	B-DS
-	O
like	O
behaviors	O
concomitant	O
with	O
the	O
elevations	O
in	O
neurotoxic	O
metabolites	O
.	O
20	O
Whereas	O
evidence	O
implicates	O
KMO	B-GP
-	O
dependent	O
kynurenine	O
metabolism	O
as	O
a	O
likely	O
pathogenic	O
mechanism	O
underlying	O
inflammation	O
-	O
induced	O
depression	B-DS
,	O
28	O
until	O
recently	O
,	O
no	O
preclinical	O
genetic	O
models	O
were	O
available	O
to	O
directly	O
test	O
this	O
hypothesis	O
and	O
brain	O
-	O
penetrant	O
KMO	B-GP
inhibitors	O
are	O
not	O
commercially	O
available	O
.	O

In	O
order	O
to	O
determine	O
whether	O
KMO	B-GP
-	O
dependent	O
neurotoxic	O
kynurenine	O
metabolism	O
mediates	O
the	O
depressive	O
-	O
like	O
behavioral	O
changes	O
following	O
peripheral	O
immune	O
challenge	O
,	O
two	O
novel	O
transgenic	O
mouse	B-OG
strains	O
were	O
generated	O
with	O
targeted	O
deletion	O
of	O
either	O
the	O
KMO	B-GP
or	O
3	B-GP
-	I-GP
hydroxyanthranilic	I-GP
acid	I-GP
dioxygenase	I-GP
(	O
HAAO	B-GP
)	O
gene	O
.	O

Inflammation	O
-	O
induced	O
depressive	O
behaviors	O
were	O
precipitated	O
in	O
control	O
or	O
transgenic	O
mice	B-OG
using	O
the	O
well	O
-	O
established	O
peripheral	O
LPS	O
challenge	O
model	O
.	O
29	O
,	O
30	O
3	O
-	O
HK	O
,	O
the	O
initial	O
substrate	O
for	O
neurotoxic	O
kynurenine	O
pathway	O
metabolism	O
,	O
was	O
directly	O
administered	O
to	O
naive	O
mice	B-OG
to	O
determine	O
the	O
behavioral	O
consequences	O
of	O
increased	O
KMO	B-GP
-	O
dependent	O
kynurenine	O
metabolites	O
.	O

Because	O
it	O
had	O
previously	O
only	O
been	O
investigated	O
at	O
the	O
whole	O
-	O
brain	O
level	O
,	O
changes	O
in	O
downstream	O
neuroactive	O
kynurenine	O
metabolism	O
in	O
behaviorally	O
salient	O
discrete	O
brain	O
regions	O
were	O
characterized	O
in	O
wild	O
-	O
type	O
(	O
WT	O
)	O
mice	B-OG
following	O
LPS	O
challenge	O
.	O

These	O
novel	O
data	O
have	O
important	O
ramifications	O
for	O
not	O
only	O
our	O
understanding	O
of	O
neuropsychiatric	O
pathology	O
during	O
inflammation	O
,	O
but	O
also	O
for	O
identification	O
of	O
novel	O
therapeutic	O
targets	O
.	O

Materials	O
and	O
methods	O

Animals	B-OG

All	O
animal	B-OG
care	O
and	O
use	O
was	O
carried	O
out	O
in	O
accord	O
with	O
the	O
Guide	O
for	O
the	O
Care	O
and	O
Use	O
of	O
Laboratory	O
Animals	B-OG
,	O
8th	O
edition	O
(	O
NRC	O
)	O
and	O
approved	O
by	O
the	O
Institutional	O
Animal	O
Care	O
and	O
Use	O
Committee	O
at	O
The	O
University	O
of	O
Texas	O
Health	O
Science	O
Center	O
at	O
San	O
Antonio	O
.	O

General	O
health	O
of	O
the	O
mice	B-OG
was	O
monitored	O
daily	O
.	O

Knockout	O
first	O
,	O
conditional	O
ready	O
KMO	B-GP
and	O
HAAO	B-GP
transgenic	O
mice	B-OG
(	O
Kmotm1a	O
(	O
KOMP	O
)	O
Wtsi	O
and	O
Haaotm1a	B-GP
(	O
KOMP	O
)	O
Wtsi	O
)	O
on	O
a	O
C57BL	O
/	O
6N	O
background	O
were	O
designed	O
and	O
generated	O
by	O
the	O
Mouse	B-OG
Biology	O
Program	O
(	O
MBP	O
,	O
www	O
.	O
mousebiology	O
.	O
org	O
)	O
at	O
the	O
University	O
of	O
California	O
Davis	O
(	O
UC	O
Davis	O
).	O

The	O
MBP	O
was	O
supported	O
by	O
the	O
Knock	O
-	O
Out	O
Mouse	B-OG
Project	O
(	O
KOMP	O
),	O
a	O
trans	O
-	O
NIH	O
initiative	O
,	O
and	O
the	O
CSD	O
Consortium	O
,	O
composed	O
of	O
the	O
Children	O
'	O
s	O
Hospital	O
Oakland	O
Research	O
Institute	O
(	O
CHORI	O
),	O
the	O
Wellcome	O
Trust	O
Sanger	O
Institute	O
and	O
UC	O
Davis	O
.	O

Vectors	O
,	O
embryonic	O
stem	O
cells	O
and	O
gene	O
information	O
related	O
to	O
these	O
mouse	B-OG
strains	O
are	O
available	O
at	O
the	O
KOMP	O
Repository	O
(	O
www	O
.	O
komp	O
.	O
org	O
)	O
maintained	O
by	O
UC	O
Davis	O
and	O
CHORI	O
.	O

Briefly	O
,	O
C57BL	O
/	O
6N	O
mouse	B-OG
embryonic	O
stem	O
cells	O
were	O
injected	O
with	O
a	O
vector	O
containing	O
a	O
transgenic	O
cassette	O
directed	O
for	O
the	O
target	O
gene	O
(	O
Figures	O
2a	O
and	O
c	O
).	O

Stem	O
cells	O
were	O
selected	O
for	O
site	O
-	O
specific	O
integration	O
of	O
the	O
transgene	O
,	O
microinjected	O
into	O
C57BL	O
/	O
6N	O
mouse	B-OG
blastocysts	O
and	O
implanted	O
into	O
C57BL	O
/	O
6N	O
female	O
mice	B-OG
.	O
31	O
During	O
transcription	O
,	O
the	O
proper	O
incorporation	O
of	O
the	O
transgene	O
into	O
the	O
target	O
gene	O
results	O
in	O
gene	O
-	O
trapping	O
between	O
the	O
reporter	O
gene	O
(	O
lacZ	B-GP
)	O
from	O
the	O
cassette	O
and	O
the	O
endogenous	O
gene	O
.	O
32	O
When	O
these	O
transcripts	O
become	O
spliced	O
together	O
,	O
an	O
insertion	O
mutation	O
is	O
created	O
resulting	O
in	O
a	O
non	O
-	O
functional	O
target	O
protein	O
.	O

The	O
presence	O
of	O
the	O
Kmo	B-GP
transgene	O
was	O
confirmed	O
by	O
RT	O
-	O
PCR	O
of	O
genomic	O
DNA	O
using	O
the	O
following	O
primers	O
:	O
5	O
′-	O
ACCAGTCAGCAGGTCCTTGTTT	O
-	O
3	O
′	O
(	O
WT	O
forward	O
primer	O
),	O
5	O
′-	O
CGCGTCGAGAAGTTCCTATTCC	O
-	O
3	O
′	O
(	O
Kmo	B-GP
transgene	O
forward	O
primer	O
)	O
and	O
5	O
′-	O
AACCCATGTTACCGTCACACAC	O
-	O
3	O
′	O
(	O
common	O
reverse	O
primer	O
;	O
Figure	O
2b	O
).	O

The	O
Haao	B-GP
transgene	O
was	O
confirmed	O
in	O
the	O
same	O
manner	O
using	O
the	O
following	O
primers	O
:	O
5	O
′-	O
GATAAGGGATTGGGGGTGTG	O
-	O
3	O
′	O
(	O
WT	O
forward	O
primer	O
),	O
5	O
′-	O
GAAAGTATAGGAACTTCGTCGAGAT	O
-	O
3	O
′	O
(	O
Haao	B-GP
transgene	O
forward	O
primer	O
)	O
and	O
5	O
′-	O
GCCAAGGTCCTTACAGTGGA	O
-	O
3	O
′	O
(	O
common	O
reverse	O
primer	O
;	O
Figure	O
2d	O
).	O

Functional	O
deletion	O
of	O
the	O
target	O
gene	O
was	O
confirmed	O
using	O
validated	O
Taqman	O
Gene	O
Expression	O
assays	O
(	O
Mm01321343_m1	O
(	O
Kmo	B-GP
)	O
and	O
Mm00517945_m1	O
(	O
Haao	B-GP
);	O
Life	O
Technologies	O
,	O
Grand	O
Island	O
,	O
NY	O
,	O
USA	O
)	O
for	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
amplification	O
of	O
steady	O
-	O
state	O
mRNA	O
(	O
data	O
not	O
shown	O
).	O

Upon	O
confirmation	O
of	O
a	O
knockout	O
genotype	O
,	O
mice	B-OG
were	O
back	O
-	O
crossed	O
with	O
C57BL	O
/	O
6J	O
mice	B-OG
(	O
Jackson	O
Laboratory	O
,	O
Bar	O
Harbor	O
,	O
ME	O
,	O
USA	O
;	O
stock	O
#	O
000664	O
)	O
for	O
five	O
generations	O
to	O
maintain	O
the	O
in	O
-	O
house	O
breeding	O
colonies	O
.	O

C57BL	O
/	O
6J	O
mice	B-OG
were	O
used	O
to	O
supplement	O
the	O
WT	O
littermate	O
control	O
group	O
when	O
needed	O
,	O
after	O
confirming	O
that	O
there	O
was	O
not	O
a	O
significant	O
difference	O
in	O
the	O
phenotypic	O
or	O
metabolic	O
responses	O
to	O
LPS	O
(	O
data	O
not	O
shown	O
).	O

Three	O
to	O
five	O
-	O
month	O
-	O
old	O
male	O
mice	B-OG
were	O
used	O
for	O
all	O
experiments	O
.	O
Ad	O
libitum	O
food	O
and	O
water	O
access	O
was	O
provided	O
at	O
all	O
times	O
.	O

Two	O
weeks	O
before	O
testing	O
,	O
mice	B-OG
were	O
individually	O
housed	O
in	O
a	O
modified	O
reverse	O
light	O
cycle	O
(	O
lights	O
on	O
2300	O
–	O
1100	O
hours	O
),	O
gently	O
handled	O
and	O
weighed	O
each	O
day	O
.	O

Treatments	O

LPS	O
(	O
Escherichia	B-OG
coli	I-OG
,	O
serotype	O
0127	O
:	O
B8	O
,	O
Sigma	O
-	O
Aldrich	O
,	O
St	O
Louis	O
,	O
MO	O
,	O
USA	O
)	O
was	O
prepared	O
in	O
endotoxin	O
-	O
free	O
saline	O
on	O
the	O
morning	O
of	O
injections	O
.	O

LPS	O
(	O
0	O
.	O
5	O
mg	O
kg	O
−	O
1	O
)	O
or	O
saline	O
was	O
injected	O
intraperitoneally	O
(	O
i	O
.	O
p	O
.)	O
24	O
h	O
before	O
behavioral	O
assessments	O
and	O
tissue	O
collection	O
.	O

3	O
-	O
HK	O
(	O
Sigma	O
-	O
Aldrich	O
)	O
was	O
dissolved	O
in	O
0	O
.	O
5	O
N	O
HCl	O
at	O
a	O
concentration	O
of	O
4	O
×,	O
diluted	O
to	O
2	O
×	O
with	O
0	O
.	O
5	O
N	O
NaOH	O
and	O
to	O
1	O
×	O
with	O
0	O
.	O
2M	O
(	O
2	O
×)	O
phosphate	O
-	O
buffered	O
saline	O
.	O

3	O
-	O
HK	O
was	O
administered	O
subcutaneously	O
at	O
0	O
.	O
0	O
,	O
3	O
.	O
33	O
or	O
10	O
mg	O
kg	O
−	O
1	O
30	O
min	O
before	O
behavioral	O
testing	O
or	O
tissue	O
collection	O
,	O
which	O
was	O
previously	O
established	O
as	O
the	O
time	O
of	O
peak	O
brain	O
concentrations	O
following	O
peripheral	O
kynurenine	O
administration	O
.	O
33	O

Treatment	O
groups	O
:	O
WT	O
and	O
KMO	B-GP
−/−	O
mice	B-OG
were	O
treated	O
(	O
i	O
.	O
p	O
.)	O
with	O
either	O
saline	O
(	O
WT	O
n	O
=	O
36	O
;	O
KMO	B-GP
−/−	O
n	O
=	O
24	O
)	O
or	O
LPS	O
(	O
WT	O
n	O
=	O
37	O
;	O
KMO	B-GP
−/−	O
n	O
=	O
24	O
),	O
followed	O
by	O
behavioral	O
testing	O
(	O
Figure	O
3	O
)	O
and	O
tissue	O
collection	O
(	O
Table	O
1	O
)	O
at	O
24	O
h	O
.	O

WT	O
mice	B-OG
were	O
injected	O
peripherally	O
(	O
subcutaneously	O
)	O
with	O
0	O
.	O
0	O
mg	O
kg	O
−	O
1	O
(	O
n	O
=	O
27	O
),	O
3	O
.	O
33	O
mg	O
kg	O
−	O
1	O
(	O
n	O
=	O
17	O
)	O
or	O
10	O
mg	O
kg	O
−	O
1	O
(	O
n	O
=	O
20	O
)	O
3	O
-	O
HK	O
,	O
followed	O
by	O
either	O
behavior	O
or	O
tissue	O
collection	O
(	O
Figure	O
4	O
).	O

WT	O
and	O
HAAO	B-GP
−/−	O
mice	B-OG
were	O
also	O
treated	O
(	O
i	O
.	O
p	O
.)	O
with	O
either	O
saline	O
(	O
WT	O
n	O
=	O
26	O
;	O
HAAO	B-GP
−/−	O
n	O
=	O
29	O
)	O
or	O
LPS	O
(	O
WT	O
n	O
=	O
29	O
;	O
HAAO	B-GP
−/−	O
n	O
=	O
31	O
),	O
followed	O
by	O
behavioral	O
assessment	O
(	O
Figure	O
5	O
)	O
and	O
tissue	O
collection	O
(	O
Table	O
1	O
)	O
at	O
24	O
h	O
.	O

Finally	O
,	O
WT	O
mice	B-OG
were	O
treated	O
(	O
i	O
.	O
p	O
.)	O
with	O
either	O
saline	O
(	O
n	O
=	O
12	O
)	O
or	O
LPS	O
(	O
n	O
=	O
12	O
)	O
and	O
brain	O
regions	O
were	O
microdissected	O
(	O
Tables	O
2	O
and	O
3	O
)	O
at	O
24	O
h	O
.	O

Animals	B-OG
were	O
randomly	O
assigned	O
to	O
treatment	O
groups	O
within	O
the	O
appropriate	O
genotype	O
,	O
and	O
data	O
were	O
collected	O
and	O
analyzed	O
by	O
a	O
treatment	O
-	O
blind	O
observer	O
.	O

Previous	O
studies	O
conducted	O
by	O
our	O
laboratory	O
using	O
similar	O
treatments	O
and	O
behaviors	O
were	O
used	O
to	O
determine	O
group	O
sample	O
size	O
,	O
which	O
provide	O
adequate	O
effect	O
size	O
.	O
16	O
,	O
33	O
,	O
34	O

Behavioral	O
testing	O

Locomotor	O
activity	O
and	O
open	O
field	O
test	O

Exploratory	O
locomotor	O
activity	O
and	O
anxiety	B-DS
-	O
like	O
behavior	O
were	O
assessed	O
24	O
h	O
post	O
-	O
LPS	O
by	O
placing	O
mice	B-OG
in	O
a	O
dimly	O
lit	O
(~	O
5	O
lux	O
)	O
40	O
×	O
40	O
cm	O
open	O
field	O
(	O
OF	O
)	O
chamber	O
for	O
5	O
min	O
.	O

Activity	O
in	O
the	O
OF	O
was	O
video	O
-	O
recorded	O
and	O
assessed	O
for	O
total	O
horizontal	O
distance	O
traveled	O
and	O
time	O
spent	O
in	O
the	O
central	O
or	O
outer	O
areas	O
using	O
Ethovision	O
XT	O
7	O
.	O
1	O
analysis	O
software	O
(	O
Noldus	O
,	O
Leesburg	O
,	O
VA	O
,	O
USA	O
)	O
as	O
previously	O
described	O
.	O
16	O
The	O
chamber	O
was	O
cleaned	O
with	O
70	O
%	O
ethanol	O
after	O
each	O
individual	O
test	O
.	O

Sucrose	O
preference	O

Three	O
days	O
before	O
LPS	O
treatment	O
,	O
mice	B-OG
were	O
trained	O
using	O
a	O
two	O
-	O
bottle	O
(	O
water	O
and	O
1	O
%	O
sucrose	O
)	O
testing	O
paradigm	O
.	O

Following	O
LPS	O
injections	O
,	O
sucrose	O
preference	O
(	O
SP	O
)	O
was	O
assessed	O
as	O
an	O
index	O
of	O
anhedonia	B-DS
-	O
like	O
behavior	O
as	O
previously	O
described	O
and	O
calculated	O
as	O
(	O
sucrose	O
intake	O
)/(	O
water	O
+	O
sucrose	O
intake	O
)	O
×	O
100	O
.	O
16	O
To	O
control	O
for	O
potential	O
place	O
preference	O
,	O
bottles	O
were	O
placed	O
on	O
the	O
outside	O
edge	O
of	O
the	O
wire	O
food	O
hopper	O
and	O
their	O
relative	O
location	O
was	O
alternated	O
daily	O
.	O

Tail	O
suspension	O
test	O

Immediately	O
after	O
the	O
OF	O
test	O
,	O
behavioral	O
despair	O
was	O
measured	O
in	O
the	O
tail	O
suspension	O
test	O
(	O
TST	O
),	O
as	O
previously	O
described	O
.	O
14	O
Immobility	O
during	O
the	O
6	O
min	O
test	O
was	O
scored	O
by	O
a	O
trained	O
treatment	O
-	O
blinded	O
observer	O
.	O

Any	O
mice	B-OG
that	O
climbed	O
their	O
tail	O
,	O
which	O
occurred	O
in	O
fewer	O
than	O
5	O
%	O
of	O
experimental	O
mice	B-OG
,	O
were	O
excluded	O
from	O
subsequent	O
data	O
analysis	O
.	O

Y	O
-	O
Maze	O

Mice	B-OG
were	O
placed	O
in	O
the	O
maze	O
and	O
allowed	O
to	O
freely	O
explore	O
for	O
8	O
min	O
.	O

The	O
movement	O
and	O
location	O
of	O
the	O
mouse	B-OG
was	O
recorded	O
from	O
an	O
overhead	O
camera	O
,	O
and	O
the	O
distance	O
traveled	O
and	O
sequence	O
of	O
arm	O
entries	O
were	O
scored	O
from	O
the	O
video	O
archive	O
.	O

An	O
entry	O
was	O
scored	O
only	O
when	O
the	O
mouse	B-OG
'	O
s	O
full	O
body	O
(	O
minus	O
tail	O
)	O
had	O
entered	O
2	O
-	O
cm	O
deep	O
into	O
the	O
arm	O
.	O

A	O
spontaneous	O
alternation	O
occurred	O
when	O
the	O
mouse	B-OG
entered	O
each	O
of	O
the	O
three	O
different	O
arms	O
sequentially	O
before	O
making	O
a	O
return	O
entry	O
to	O
an	O
already	O
visited	O
arm	O
.	O

Behavioral	O
timeline	O

Before	O
treatment	O
(	O
saline	O
or	O
LPS	O
i	O
.	O
p	O
.),	O
mice	B-OG
were	O
trained	O
on	O
the	O
two	O
-	O
bottle	O
SP	O
testing	O
paradigm	O
,	O
and	O
then	O
SP	O
data	O
were	O
collected	O
during	O
the	O
24	O
h	O
following	O
treatment	O
and	O
before	O
behavioral	O
testing	O
.	O

At	O
24	O
h	O
following	O
treatment	O
,	O
mice	B-OG
underwent	O
testing	O
in	O
the	O
OF	O
and	O
TST	O
or	O
the	O
Y	O
-	O
maze	O
immediately	O
followed	O
by	O
tissue	O
collection	O
(	O
as	O
described	O
below	O
).	O

For	O
peripheral	O
3	O
-	O
HK	O
experiments	O
,	O
mice	B-OG
were	O
injected	O
subcutaneously	O
30	O
min	O
before	O
either	O
the	O
TST	O
,	O
OF	O
,	O
Y	O
-	O
maze	O
,	O
a	O
shortened	O
2	O
h	O
SP	O
test	O
or	O
tissue	O
collection	O
.	O

Liquid	O
chromatography	O
/	O
mass	O
spectrometry	O

Either	O
following	O
behavior	O
at	O
~	O
25	O
h	O
post	O
-	O
LPS	O
treatment	O
or	O
30	O
min	O
following	O
subcutaneous	O
3	O
-	O
HK	O
administration	O
,	O
tissues	O
were	O
collected	O
for	O
analysis	O
.	O

Mice	B-OG
were	O
killed	O
by	O
carbon	O
dioxide	O
asphyxiation	O
and	O
venous	O
blood	O
was	O
collected	O
into	O
heparinized	O
tubes	O
for	O
separation	O
of	O
plasma	O
.	O

Then	O
,	O
mice	B-OG
were	O
immediately	O
perfused	O
with	O
ice	O
-	O
cold	O
heparinized	O
sterile	O
saline	O
before	O
collection	O
of	O
whole	O
-	O
brain	O
or	O
microdissection	O
of	O
dorsal	O
hippocampus	O
,	O
ventral	O
hippocampus	O
,	O
central	O
amygdala	O
and	O
nucleus	O
accumbens	O
.	O

Microdissections	O
were	O
conducted	O
using	O
a	O
brain	O
matrix	O
(	O
Stoelting	O
,	O
Wood	O
Dale	O
,	O
IL	O
,	O
USA	O
)	O
and	O
serial	O
1	O
-	O
mm	O
coronal	O
brain	O
sections	O
(	O
based	O
on	O
stereological	O
coordinates	O
in	O
a	O
mouse	B-OG
brain	O
atlas35	O
).	O

All	O
tissue	O
samples	O
were	O
stored	O
at	O
−	O
80	O
°	O
C	O
until	O
use	O
.	O

Samples	O
were	O
prepared	O
for	O
liquid	O
chromatography	O
/	O
mass	O
spectrometry	O
(	O
LC	O
/	O
MS	O
)	O
and	O
analyzed	O
for	O
kynurenine	O
metabolites	O
as	O
previously	O
described	O
.	O
20	O
Briefly	O
,	O
thawed	O
plasma	O
samples	O
were	O
diluted	O
with	O
5	O
×	O
0	O
.	O
2	O
%	O
acetic	O
acid	O
and	O
1	O
mM	O
internal	O
standards	O
,	O
transferred	O
to	O
Amicon	O
Ultra	O
filters	O
(	O
Millipore	O
,	O
Billerica	O
,	O
MA	O
,	O
USA	O
)	O
and	O
centrifuged	O
at	O
13	O
500	O
g	O
for	O
1	O
hour	O
at	O
4	O
°	O
C	O
.	O

Frozen	O
brain	O
tissue	O
was	O
diluted	O
with	O
3	O
×	O
0	O
.	O
2	O
%	O
acetic	O
acid	O
and	O
1	O
mM	O
internal	O
standards	O
and	O
then	O
homogenized	O
at	O
4	O
°	O
C	O
using	O
an	O
Omni	O
International	O
Bead	O
Ruptor	O
24	O
Homogenizer	O
(	O
Kennesaw	O
,	O
GA	O
,	O
USA	O
)	O
with	O
1	O
.	O
4	O
mm	O
zirconium	O
ceramic	O
oxide	O
beads	O
(	O
Omni	O
International	O
)	O
and	O
settings	O
of	O
(	O
pulse	O
duration	O
:	O
45	O
s	O
,	O
pulse	O
number	O
:	O
2	O
,	O
rest	O
interval	O
:	O
15	O
s	O
).	O

The	O
brain	O
homogenate	O
was	O
filtered	O
as	O
the	O
plasma	O
.	O

LC	O
/	O
MS	O
was	O
performed	O
on	O
a	O
Thermo	O
Fisher	O
Scientific	O
Q	O
Exactive	O
mass	O
spectrometer	O
(	O
Waltham	O
,	O
MA	O
,	O
USA	O
)	O
with	O
online	O
separation	O
by	O
a	O
Thermo	O
Fisher	O
Scientific	O
Dionex	O
UltiMate	O
3000	O
HPLC	O
and	O
the	O
resulting	O
data	O
were	O
analyzed	O
using	O
Xcalibur	O
2	O
.	O
2	O
(	O
Thermo	O
Fisher	O
Scientific	O
)	O
in	O
the	O
Mass	O
Spectrometry	O
Core	O
Facility	O
at	O
the	O
University	O
of	O
Texas	O
Health	O
Science	O
Center	O
at	O
San	O
Antonio	O
.	O

QA	O
and	O
3	O
-	O
HAA	O
were	O
not	O
reliably	O
measured	O
in	O
microdissected	O
brain	O
region	O
samples	O
because	O
of	O
small	O
sample	O
size	O
,	O
nor	O
was	O
QA	O
reliably	O
detected	O
in	O
whole	O
-	O
brain	O
samples	O
.	O

Statistical	O
analysis	O

All	O
statistical	O
analyses	O
were	O
performed	O
using	O
SigmaPlot	O
12	O
.	O
0	O
(	O
Systat	O
Software	O
,	O
San	O
Jose	O
,	O
CA	O
,	O
USA	O
)	O
and	O
data	O
represent	O
group	O
means	O
±	O
s	O
.	O
e	O
.	O
m	O
.	O

Behavioral	O
data	O
are	O
presented	O
as	O
%	O
Saline	O
(	O
saline	O
or	O
LPS	O
i	O
.	O
p	O
.)	O
or	O
%	O
Vehicle	O
(	O
3	O
-	O
HK	O
subcutaneous	O
)	O
and	O
were	O
calculated	O
based	O
on	O
saline	O
within	O
the	O
individual	O
genotype	O
or	O
on	O
vehicle	O
.	O

Spurious	O
data	O
were	O
identified	O
as	O
previously	O
described33	O
and	O
analyzed	O
with	O
either	O
a	O
one	O
-	O
tailed	O
t	O
-	O
test	O
,	O
a	O
one	O
-	O
or	O
two	O
-	O
way	O
analysis	O
of	O
variance	O
.	O

When	O
a	O
significant	O
interaction	O
was	O
identified	O
,	O
post	O
hoc	O
analyses	O
were	O
completed	O
using	O
the	O
Holm	O
–	O
Sidak	O
method	O
for	O
pairwise	O
multiple	O
comparisons	O
to	O
identify	O
significant	O
differences	O
between	O
groups	O
.	O

Significant	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
within	O
-	O
group	O
differences	O
are	O
denoted	O
as	O
such	O
(*),	O
whereas	O
significant	O
same	O
treatment	O
between	O
-	O
group	O
differences	O
are	O
denoted	O
as	O
such	O
(+).	O

Results	O

KMO	B-GP
mediates	O
distinct	O
inflammation	O
-	O
induced	O
depressive	O
-	O
like	O
behaviors	O

Mice	B-OG
were	O
tested	O
in	O
the	O
TST	O
(	O
Figure	O
3a	O
)	O
24	O
h	O
after	O
i	O
.	O
p	O
.	O

LPS	O
or	O
saline	O
,	O
and	O
a	O
significant	O
genotype	O
×	O
treatment	O
interaction	O
(	O
P	O
=	O
0	O
.	O
009	O
)	O
was	O
identified	O
.	O

WT	O
mice	B-OG
exhibited	O
a	O
significant	O
increase	O
in	O
duration	O
spent	O
immobile	O
following	O
LPS	O
injections	O
(	O
P	O
=	O
0	O
.	O
029	O
versus	O
saline	O
),	O
similar	O
to	O
previously	O
observed	O
LPS	O
effects	O
in	O
the	O
TST	O
.	O
14	O
However	O
,	O
LPS	O
failed	O
to	O
cause	O
an	O
increase	O
in	O
the	O
duration	O
of	O
immobility	O
in	O
KMO	B-GP
−/−	O
mice	B-OG
.	O

LPS	O
caused	O
a	O
significant	O
reduction	O
in	O
SP	O
(	O
Figure	O
3b	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
that	O
was	O
not	O
different	O
between	O
genotypes	O
,	O
and	O
similarly	O
the	O
duration	O
of	O
time	O
spent	O
in	O
the	O
central	O
area	O
of	O
an	O
OF	O
was	O
significantly	O
reduced	O
by	O
LPS	O
-	O
independent	O
of	O
genotype	O
(	O
Figure	O
2c	O
,	O
P	O
<	O
0	O
.	O
001	O
).	O

Thigmotaxis	O
(	O
Figure	O
3d	O
),	O
wall	O
-	O
hugging	O
behavior	O
,	O
was	O
increased	O
after	O
LPS	O
in	O
both	O
WT	O
(	O
P	O
=	O
0	O
.	O
012	O
)	O
and	O
KMO	B-GP
−/−	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
mice	B-OG
,	O
but	O
to	O
a	O
greater	O
extent	O
in	O
the	O
KMO	B-GP
-	O
deficient	O
mice	B-OG
(	O
P	O
<	O
0	O
.	O
001	O
).	O

Overall	O
distance	O
traveled	O
in	O
the	O
OF	O
was	O
reduced	O
modestly	O
,	O
but	O
significantly	O
,	O
by	O
LPS	O
treatment	O
(	O
Supplementary	O
Figure	O
1A	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
independent	O
of	O
genotype	O
,	O
as	O
was	O
LPS	O
-	O
induced	O
reduction	O
in	O
body	O
weight	O
(	O
Supplementary	O
Figure	O
1B	O
,	O
P	O
<	O
0	O
.	O
001	O
).	O

A	O
significant	O
genotype	O
×	O
treatment	O
interaction	O
(	O
F1	O
,	O
23	O
=	O
5	O
.	O
10	O
,	O
P	O
=	O
0	O
.	O
034	O
)	O
was	O
apparent	O
for	O
spontaneous	O
alternations	O
during	O
the	O
Y	O
-	O
maze	O
test	O
(	O
Figure	O
3e	O
),	O
where	O
LPS	O
reduced	O
alternations	O
in	O
WT	O
(	O
P	O
=	O
0	O
.	O
046	O
),	O
but	O
not	O
in	O
KMO	B-GP
−/−	O
mice	B-OG
.	O

3	O
-	O
HK	O
dose	O
-	O
dependently	O
induces	O
a	O
depressive	O
-	O
like	O
behavioral	O
phenotype	O

3	O
-	O
HK	O
was	O
administered	O
subcutaneously	O
30	O
min	O
before	O
behavioral	O
testing	O
at	O
the	O
indicated	O
doses	O
.	O

3	O
-	O
HK	O
induced	O
a	O
dose	O
-	O
dependent	O
increase	O
in	O
the	O
duration	O
of	O
immobility	O
during	O
the	O
TST	O
(	O
Figure	O
4a	O
,	O
P	O
=	O
0	O
.	O
012	O
).	O

SP	O
,	O
measured	O
during	O
a	O
2	O
-	O
h	O
probe	O
beginning	O
30	O
min	O
post	O
injection	O
,	O
was	O
unaffected	O
by	O
3	O
-	O
HK	O
administration	O
(	O
Figure	O
4b	O
).	O

The	O
duration	O
of	O
time	O
spent	O
in	O
the	O
central	O
area	O
of	O
an	O
OF	O
was	O
significantly	O
increased	O
by	O
3	O
-	O
HK	O
administration	O
(	O
Figure	O
4c	O
,	O
P	O
=	O
0	O
.	O
013	O
);	O
however	O
,	O
thigmotaxis	O
behavior	O
failed	O
to	O
reach	O
significance	O
(	O
Figure	O
4c	O
).	O

Importantly	O
,	O
general	O
locomotor	O
activity	O
in	O
the	O
OF	O
,	O
as	O
evaluated	O
by	O
distance	O
traveled	O
,	O
was	O
not	O
significantly	O
affected	O
by	O
3	O
-	O
HK	O
administration	O
(	O
data	O
not	O
shown	O
).	O

Similar	O
to	O
TST	O
immobility	O
,	O
exogenous	O
3	O
-	O
HK	O
administration	O
significantly	O
reduced	O
spontaneous	O
alternations	O
during	O
the	O
Y	O
-	O
maze	O
test	O
(	O
Figure	O
4e	O
,	O
P	O
=	O
0	O
.	O
007	O
)	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

Peripheral	O
3	O
-	O
HK	O
administration	O
dose	O
-	O
dependently	O
increased	O
3	O
-	O
HK	O
concentration	O
in	O
the	O
plasma	O
(	O
Figure	O
4f	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
in	O
line	O
with	O
behavioral	O
changes	O
observed	O
.	O

Similarly	O
,	O
central	O
concentrations	O
of	O
3	O
-	O
HK	O
(	O
Figure	O
4g	O
)	O
were	O
dose	O
-	O
dependently	O
elevated	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
in	O
response	O
to	O
peripheral	O
3	O
-	O
HK	O
injections	O
.	O

HAAO	B-GP
null	O
mice	B-OG
are	O
protected	O
from	O
peripheral	O
LPS	O
-	O
induced	O
behavioral	O
despair	O

Twenty	O
-	O
four	O
hours	O
after	O
LPS	O
or	O
saline	O
treatment	O
,	O
depressive	O
-	O
like	O
behaviors	O
were	O
assessed	O
in	O
HAAO	B-GP
−/−	O
or	O
WT	O
.	O

LPS	O
administration	O
caused	O
a	O
40	O
%	O
increase	O
in	O
the	O
duration	O
of	O
immobility	O
in	O
WT	O
mice	B-OG
in	O
the	O
TST	O
;	O
however	O
,	O
HAAO	B-GP
−/−	O
mice	B-OG
were	O
entirely	O
protected	O
from	O
this	O
effect	O
(	O
Figure	O
5a	O
,	O
P	O
=	O
0	O
.	O
013	O
).	O

HAAO	B-GP
−/−	O
mice	B-OG
had	O
similar	O
LPS	O
treatment	O
responses	O
as	O
WT	O
mice	B-OG
when	O
assessed	O
for	O
anhedonia	B-DS
and	O
anxiety	B-DS
-	O
like	O
behavior	O
.	O

Following	O
LPS	O
treatment	O
,	O
there	O
was	O
a	O
significant	O
decrease	O
in	O
SP	O
caused	O
by	O
LPS	O
(	O
Figure	O
5b	O
)	O
in	O
both	O
HAAO	B-GP
−/−	O
and	O
WT	O
mice	B-OG
(	O
P	O
<	O
0	O
.	O
001	O
),	O
and	O
although	O
no	O
interaction	O
was	O
present	O
,	O
a	O
modest	O
but	O
significant	O
overall	O
reduction	O
in	O
SP	O
was	O
apparent	O
in	O
HAAO	B-GP
−/−	O
mice	B-OG
(	O
P	O
<	O
0	O
.	O
001	O
).	O

In	O
the	O
OF	O
test	O
,	O
LPS	O
caused	O
a	O
reduction	O
in	O
the	O
duration	O
of	O
time	O
spent	O
in	O
the	O
central	O
area	O
(	O
Figure	O
5c	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
and	O
an	O
increase	O
in	O
thigmotaxis	O
behavior	O
(	O
Figure	O
5d	O
,	O
P	O
<	O
0	O
.	O
001	O
);	O
however	O
,	O
there	O
was	O
no	O
significant	O
effect	O
of	O
genotype	O
.	O

Similar	O
to	O
KMO	B-GP
−/−	O
mice	B-OG
,	O
distance	O
traveled	O
during	O
the	O
OF	O
(	O
Supplementary	O
Figure	O
1C	O
)	O
was	O
reduced	O
24	O
h	O
following	O
LPS	O
treatment	O
independent	O
of	O
genotype	O
(	O
P	O
<	O
0	O
.	O
001	O
),	O
and	O
LPS	O
precipitated	O
a	O
reduction	O
in	O
body	O
weight	O
that	O
was	O
not	O
different	O
between	O
genotypes	O
(	O
Supplementary	O
Figure	O
1D	O
,	O
P	O
<	O
0	O
.	O
001	O
).	O

In	O
addition	O
,	O
there	O
was	O
a	O
significant	O
genotype	O
×	O
treatment	O
interaction	O
in	O
spontaneous	O
alternations	O
assessed	O
in	O
the	O
Y	O
-	O
maze	O
(	O
Figure	O
5e	O
,	O
P	O
=	O
0	O
.	O
011	O
),	O
in	O
which	O
LPS	O
treatment	O
induced	O
a	O
reduction	O
in	O
WT	O
mice	B-OG
(	O
P	O
=	O
0	O
.	O
041	O
)	O
and	O
not	O
in	O
HAAO	B-GP
−/−	O
mice	B-OG
.	O

Characterization	O
of	O
brain	O
and	O
plasma	O
kynurenine	O
metabolism	O
in	O
KMO	B-GP
and	O
HAAO	B-GP
knockout	O
mice	B-OG

Full	O
statistical	O
analysis	O
is	O
indicated	O
in	O
the	O
table	O
,	O
and	O
,	O
for	O
the	O
sake	O
of	O
clarity	O
,	O
parsimonious	O
reporting	O
of	O
significant	O
effects	O
are	O
reported	O
here	O
.	O

To	O
determine	O
the	O
consequence	O
of	O
targeted	O
deletions	O
of	O
Kmo	B-GP
and	O
Haao	B-GP
genes	O
on	O
central	O
kynurenine	O
pathway	O
metabolism	O
(	O
Figure	O
1	O
),	O
cerebral	O
levels	O
of	O
tryptophan	O
and	O
kynurenine	O
metabolites	O
were	O
measured	O
in	O
WT	O
,	O
KMO	B-GP
−/−	O
and	O
HAAO	B-GP
−/−	O
mice	B-OG
24	O
h	O
after	O
LPS	O
or	O
saline	O
administration	O
(	O
Table	O
1	O
).	O

There	O
was	O
a	O
significant	O
main	O
effect	O
of	O
both	O
treatment	O
and	O
genotype	O
on	O
the	O
concentration	O
of	O
central	O
tryptophan	O
(	O
μM	O
,	O
Row	O
1	O
).	O

Consistent	O
with	O
previous	O
findings	O
,	O
20	O
LPS	O
treatment	O
resulted	O
in	O
an	O
elevation	O
in	O
central	O
kynurenine	O
levels	O
(	O
μM	O
,	O
Row	O
2	O
)	O
in	O
WT	O
,	O
KMO	B-GP
−/−	O
and	O
HAAO	B-GP
−/−	O
mice	B-OG
.	O

However	O
,	O
there	O
was	O
a	O
significant	O
interaction	O
between	O
genotype	O
and	O
treatment	O
as	O
KMO	B-GP
−/−	O
mice	B-OG
had	O
substantially	O
higher	O
brain	O
kynurenine	O
levels	O
.	O

3	O
-	O
HK	O
(	O
μM	O
,	O
Row	O
3	O
)	O
was	O
not	O
detected	O
in	O
the	O
brain	O
of	O
KMO	B-GP
−/−	O
mice	B-OG
,	O
and	O
was	O
higher	O
in	O
HAAO	B-GP
−/−	O
mice	B-OG
relative	O
to	O
WT	O
mice	B-OG
.	O

However	O
,	O
there	O
was	O
a	O
significant	O
LPS	O
-	O
induced	O
increase	O
in	O
3	O
-	O
HK	O
in	O
WT	O
mice	B-OG
,	O
whereas	O
there	O
was	O
no	O
treatment	O
effect	O
in	O
HAAO	B-GP
−/−	O
mice	B-OG
.	O

Downstream	O
of	O
3	O
-	O
HK	O
,	O
there	O
was	O
a	O
significant	O
interaction	O
between	O
genotype	O
and	O
treatment	O
on	O
the	O
concentration	O
of	O
central	O
3	O
-	O
HAA	O
(	O
μM	O
,	O
Row	O
4	O
).	O

This	O
effect	O
is	O
largely	O
driven	O
by	O
the	O
elevation	O
of	O
central	O
3	O
-	O
HAA	O
in	O
HAAO	B-GP
−/−	O
mice	B-OG
.	O

QA	O
was	O
not	O
reliably	O
detected	O
in	O
any	O
of	O
the	O
brain	O
samples	O
in	O
our	O
study	O
.	O

KA	O
(	O
μM	O
,	O
Row	O
6	O
)	O
was	O
markedly	O
elevated	O
in	O
KMO	B-GP
−/−	O
mice	B-OG
and	O
decreased	O
in	O
HAAO	B-GP
−/−	O
mice	B-OG
,	O
with	O
no	O
significant	O
effect	O
of	O
LPS	O
.	O

Plasma	O
tryptophan	O
levels	O
(	O
μM	O
,	O
Row	O
7	O
)	O
varied	O
between	O
genotype	O
,	O
but	O
were	O
significantly	O
reduced	O
by	O
LPS	O
in	O
WT	O
,	O
KMO	B-GP
−/−	O
and	O
HAAO	B-GP
−/−	O
mice	B-OG
.	O

Kynurenine	O
levels	O
(	O
μM	O
,	O
Row	O
8	O
)	O
were	O
substantially	O
higher	O
in	O
KMO	B-GP
−/−	O
mice	B-OG
overall	O
.	O

3	O
-	O
HK	O
(	O
μM	O
,	O
Row	O
9	O
)	O
was	O
detected	O
in	O
plasma	O
of	O
all	O
mice	B-OG
,	O
although	O
near	O
the	O
lower	O
limit	O
of	O
detection	O
in	O
KMO	B-GP
−/−	O
mice	B-OG
.	O

LPS	O
increased	O
3	O
-	O
HK	O
levels	O
in	O
both	O
WT	O
and	O
HAAO	B-GP
−/−	O
mice	B-OG
,	O
but	O
not	O
in	O
KMO	B-GP
−/−	O
mice	B-OG
.	O

Plasma	O
3	O
-	O
HAA	O
(	O
μM	O
,	O
Row	O
10	O
)	O
was	O
not	O
detected	O
in	O
WT	O
or	O
KMO	B-GP
−/−	O
mice	B-OG
,	O
and	O
there	O
was	O
no	O
LPS	O
treatment	O
effect	O
in	O
HAAO	B-GP
−/−	O
mice	B-OG
.	O

QA	O
levels	O
(	O
μM	O
,	O
Row	O
11	O
)	O
varied	O
by	O
genotype	O
with	O
no	O
effect	O
of	O
treatment	O
.	O

Finally	O
,	O
there	O
was	O
a	O
significant	O
genotype	O
×	O
treatment	O
interaction	O
in	O
the	O
concentration	O
of	O
plasma	O
KA	O
(	O
μM	O
,	O
Row	O
12	O
).	O

This	O
effect	O
was	O
driven	O
by	O
a	O
25	O
–	O
30	O
-	O
fold	O
increase	O
in	O
KA	O
levels	O
in	O
the	O
KMO	B-GP
−/−	O
mice	B-OG
.	O

Overall	O
,	O
LPS	O
reduced	O
plasma	O
KA	O
levels	O
.	O

Kynurenine	O
metabolism	O
within	O
discrete	O
,	O
behaviorally	O
relevant	O
,	O
brain	O
regions	O
following	O
peripheral	O
immune	O
challenge	O
with	O
LPS	O

Full	O
statistical	O
analysis	O
is	O
indicated	O
in	O
the	O
table	O
,	O
and	O
,	O
for	O
the	O
sake	O
of	O
clarity	O
,	O
parsimonious	O
reporting	O
of	O
significant	O
effects	O
are	O
reported	O
here	O
.	O

To	O
determine	O
whether	O
region	O
-	O
specific	O
differences	O
in	O
kynurenine	O
metabolism	O
underlie	O
the	O
distinct	O
neurotoxic	O
metabolism	O
-	O
dependent	O
behavioral	O
profile	O
,	O
brain	O
region	O
metabolite	O
concentrations	O
were	O
determined	O
24	O
h	O
post	O
-	O
saline	O
or	O
LPS	O
treatment	O
(	O
Table	O
2	O
).	O

In	O
the	O
dorsal	O
hippocampus	O
,	O
both	O
tryptophan	O
and	O
kynurenine	O
concentrations	O
(	O
μM	O
)	O
increased	O
following	O
LPS	O
treatment	O
.	O

Neuroactive	O
kynurenine	O
metabolism	O
also	O
increased	O
with	O
elevations	O
in	O
3	O
-	O
HK	O
(	O
μM	O
),	O
3	O
-	O
HAA	O
(	O
μM	O
)	O
and	O
XA	O
(	O
μM	O
),	O
whereas	O
KA	O
(	O
μM	O
)	O
remained	O
unchanged	O
.	O

XA	O
has	O
been	O
reported	O
to	O
influence	O
synaptic	O
transmission	O
as	O
a	O
metabotropic	B-GP
glutamate	I-GP
receptor	I-GP
group	I-GP
II	I-GP
ligand	O
and	O
a	O
vesicular	B-GP
glutamate	I-GP
transporter	I-GP
inhibitor	O
.	O
36	O
,	O
37	O
In	O
the	O
ventral	O
hippocampus	O
,	O
LPS	O
treatment	O
also	O
increased	O
kynurenine	O
and	O
XA	O
.	O

However	O
,	O
no	O
other	O
metabolites	O
were	O
altered	O
by	O
LPS	O
.	O

In	O
the	O
central	O
amygdala	O
,	O
tryptophan	O
and	O
kynurenine	O
concentrations	O
increased	O
in	O
response	O
to	O
LPS	O
treatment	O
.	O

3	O
-	O
HK	O
,	O
XA	O
and	O
KA	O
were	O
also	O
significantly	O
elevated	O
following	O
LPS	O
treatment	O
.	O

In	O
the	O
nucleus	O
accumbens	O
,	O
tryptophan	O
and	O
all	O
kynurenine	O
metabolites	O
were	O
increased	O
following	O
LPS	O
treatment	O
as	O
in	O
the	O
central	O
amygdala	O
.	O

3	O
-	O
HAA	O
was	O
not	O
detected	O
in	O
either	O
the	O
central	O
amygdala	O
or	O
the	O
nucleus	O
accumbens	O
.	O

To	O
compare	O
the	O
relative	O
LPS	O
effect	O
between	O
brain	O
regions	O
,	O
metabolite	O
changes	O
were	O
normalized	O
as	O
%	O
saline	O
and	O
analyzed	O
(	O
Table	O
3	O
).	O

There	O
was	O
a	O
main	O
effect	O
of	O
region	O
on	O
tryptophan	O
concentration	O
change	O
following	O
LPS	O
treatment	O
,	O
whereby	O
tryptophan	O
was	O
significantly	O
higher	O
in	O
the	O
central	O
amygdala	O
than	O
the	O
ventral	O
or	O
dorsal	O
hippocampus	O
.	O

LPS	O
-	O
induced	O
increases	O
in	O
kynurenine	O
,	O
3	O
-	O
HK	O
and	O
XA	O
were	O
comparable	O
across	O
the	O
different	O
brain	O
regions	O
.	O

Although	O
3	O
-	O
HAA	O
was	O
not	O
detected	O
in	O
the	O
central	O
amygdala	O
or	O
nucleus	O
accumbens	O
,	O
it	O
was	O
increased	O
to	O
a	O
greater	O
extent	O
in	O
dorsal	O
compared	O
with	O
ventral	O
hippocampus	O
.	O

There	O
was	O
also	O
a	O
significant	O
effect	O
of	O
region	O
on	O
LPS	O
-	O
induced	O
KA	O
.	O

This	O
effect	O
was	O
driven	O
by	O
significantly	O
greater	O
LPS	O
-	O
induced	O
increase	O
in	O
nucleus	O
accumbens	O
and	O
central	O
amygdala	O
compared	O
with	O
hippocampal	O
subregions	O
.	O

Discussion	O

The	O
kynurenine	O
pathway	O
of	O
tryptophan	O
metabolism	O
has	O
been	O
heavily	O
implicated	O
as	O
a	O
pathogenic	O
factor	O
in	O
the	O
development	O
of	O
depression	B-DS
,	O
particularly	O
within	O
the	O
context	O
of	O
inflammation	O
-	O
associated	O
depression	B-DS
.	O

We	O
and	O
others	O
have	O
demonstrated	O
that	O
IDO	B-GP
,	O
the	O
rate	O
-	O
limiting	O
step	O
of	O
kynurenine	O
metabolism	O
(	O
Figure	O
1	O
),	O
directly	O
mediates	O
the	O
induction	O
of	O
depressive	O
-	O
like	O
behaviors	O
in	O
response	O
to	O
peripheral	O
immune	O
challenge	O
in	O
preclinical	O
models	O
.	O
14	O
,	O
16	O
,	O
33	O
However	O
,	O
the	O
generation	O
of	O
neuroactive	O
kynurenine	O
metabolites	O
occurs	O
downstream	O
of	O
IDO	B-GP
.	O
20	O
Whereas	O
emergent	O
clinical	O
and	O
preclinical	O
data	O
suggest	O
that	O
shifting	O
the	O
balance	O
of	O
downstream	O
kynurenine	O
metabolism	O
to	O
favor	O
production	O
of	O
neurotoxic	O
kynurenines	O
drives	O
depressive	O
symptoms	O
,	O
19	O
,	O
20	O
no	O
mechanistic	O
studies	O
have	O
been	O
performed	O
to	O
directly	O
test	O
this	O
hypothesis	O
.	O

Here	O
,	O
we	O
utilized	O
two	O
novel	O
transgenic	O
mouse	B-OG
strains	O
with	O
targeted	O
deletion	O
of	O
either	O
KMO	B-GP
or	O
HAAO	B-GP
(	O
Figure	O
1	O
)	O
to	O
determine	O
whether	O
neurotoxic	O
kynurenine	O
metabolism	O
causes	O
the	O
development	O
of	O
depressive	O
behaviors	O
following	O
peripheral	O
immune	O
activation	O
with	O
LPS	O
(	O
bacterial	O
endotoxin	O
).	O

KMO	B-GP
−/−	O
mice	B-OG
do	O
not	O
generate	O
detectible	O
3	O
-	O
HK	O
in	O
the	O
brain	O
before	O
or	O
after	O
LPS	O
challenge	O
(	O
Table	O
1	O
).	O

In	O
contrast	O
to	O
inhibition	O
of	O
IDO	B-GP
,	O
targeted	O
deletion	O
of	O
KMO	B-GP
inhibited	O
only	O
a	O
specific	O
subset	O
of	O
LPS	O
-	O
induced	O
depressive	O
-	O
like	O
behaviors	O
(	O
Figure	O
3	O
).	O

Direct	O
administration	O
of	O
3	O
-	O
HK	O
,	O
the	O
metabolic	O
product	O
of	O
KMO	B-GP
,	O
induced	O
the	O
development	O
of	O
depressive	O
-	O
like	O
behaviors	O
that	O
were	O
attenuated	O
in	O
the	O
KMO	B-GP
−/−	O
mice	B-OG
(	O
Figure	O
4	O
).	O

Although	O
QA	O
was	O
not	O
reliably	O
detected	O
in	O
brain	O
tissue	O
(	O
Table	O
1	O
),	O
a	O
reduction	O
in	O
neurotoxic	O
metabolism	O
would	O
presumably	O
result	O
in	O
the	O
generation	O
of	O
less	O
QA	O
.	O

Therefore	O
,	O
LPS	O
-	O
induced	O
depressive	O
behavior	O
was	O
measured	O
in	O
HAAO	B-GP
−/−	O
mice	B-OG
,	O
and	O
these	O
mice	B-OG
were	O
also	O
protected	O
from	O
the	O
development	O
of	O
the	O
same	O
specific	O
depressive	O
-	O
like	O
behaviors	O
(	O
Figure	O
5	O
).	O

Together	O
,	O
these	O
data	O
confirm	O
that	O
KMO	B-GP
-	O
and	O
HAAO	B-GP
-	O
dependent	O
neurotoxic	O
kynurenine	O
metabolism	O
directly	O
mediates	O
the	O
development	O
of	O
inflammation	O
-	O
induced	O
behavior	O
despair	O
and	O
working	O
memory	B-DS
deficits	I-DS
;	O
behaviors	O
regulated	O
by	O
hippocampal	O
-	O
dependent	O
neurocircuitry	O
.	O

Previous	O
research	O
in	O
this	O
area	O
has	O
suffered	O
from	O
an	O
overall	O
lack	O
of	O
functional	O
precision	O
,	O
as	O
studies	O
that	O
measured	O
kynurenine	O
metabolism	O
downstream	O
of	O
IDO	B-GP
have	O
evaluated	O
only	O
CSF	O
in	O
patients	O
or	O
whole	O
-	O
brain	O
tissue	O
in	O
rodents	B-OG
.	O
19	O
,	O
20	O
For	O
example	O
,	O
Raison	O
et	O
al	O
.	O
19	O
showed	O
that	O
the	O
concentration	O
of	O
QA	O
in	O
the	O
CSF	O
was	O
positively	O
correlated	O
with	O
depression	B-DS
scores	O
of	O
controls	O
and	O
subjects	O
receiving	O
interferon	B-GP
immunotherapy	O
.	O
19	O
In	O
addition	O
,	O
the	O
first	O
preclinical	O
study	O
to	O
investigate	O
the	O
role	O
of	O
QA	O
in	O
driving	O
depressive	O
symptoms	O
showed	O
that	O
LPS	O
-	O
induced	O
depressive	O
behaviors	O
could	O
be	O
mitigated	O
in	O
inbred	O
C57BL	O
/	O
6	O
mice	B-OG
by	O
the	O
NMDAR	B-GP
,	O
ketamine	O
,	O
suggesting	O
a	O
pathogenic	O
role	O
for	O
QA	O
.	O
20	O
Metabolic	O
analysis	O
in	O
the	O
study	O
by	O
Walker	O
et	O
al	O
.	O
20	O
indicated	O
that	O
LPS	O
caused	O
a	O
shift	O
toward	O
neurotoxic	O
metabolism	O
in	O
whole	O
-	O
brain	O
tissue	O
of	O
a	O
separate	O
group	O
of	O
CD	O
-	O
1	O
outbred	O
mice	B-OG
.	O
20	O
Here	O
,	O
we	O
report	O
,	O
for	O
we	O
believe	O
the	O
first	O
time	O
,	O
direct	O
evidence	O
that	O
directly	O
implicates	O
KMO	B-GP
-	O
dependent	O
kynurenine	O
metabolism	O
in	O
LPS	O
-	O
induced	O
depression	B-DS
.	O

Further	O
,	O
as	O
only	O
specific	O
behaviors	O
were	O
mitigated	O
by	O
genetic	O
inhibition	O
of	O
neurotoxic	O
kynurenine	O
metabolism	O
,	O
the	O
data	O
suggested	O
that	O
kynurenine	O
metabolism	O
might	O
differ	O
between	O
discrete	O
brain	O
regions	O
.	O

Indeed	O
,	O
Frenois	O
et	O
al	O
.	O
38	O
demonstrated	O
that	O
neuronal	O
activation	O
following	O
peripheral	O
LPS	O
challenge	O
of	O
C57BL6	O
/	O
J	O
mice	B-OG
(	O
measured	O
by	O
FosB	B-GP
/	O
Δ	O
FosB	B-GP
immunohistochemistry	O
)	O
was	O
not	O
uniformly	O
increased	O
.	O
38	O
Rather	O
,	O
discrete	O
regions	O
with	O
known	O
relevance	O
to	O
depressive	O
behavioral	O
domains	O
were	O
more	O
strongly	O
increased	O
,	O
including	O
hippocampus	O
,	O
nucleus	O
accumbens	O
and	O
central	O
amygdala	O
.	O
38	O

Whereas	O
a	O
previous	O
report	O
by	O
Giorgini	O
et	O
al	O
.	O
39	O
characterized	O
the	O
metabolic	O
changes	O
that	O
occur	O
in	O
response	O
to	O
a	O
KMO	B-GP
deficiency	O
in	O
a	O
separate	O
strain	O
of	O
mice	B-OG
,	O
39	O
the	O
data	O
in	O
Figure	O
3	O
are	O
the	O
first	O
to	O
demonstrate	O
the	O
significance	O
of	O
a	O
KMO	B-GP
genetic	O
deletion	O
on	O
the	O
behavioral	O
consequences	O
of	O
peripheral	O
LPS	O
administration	O
.	O

KMO	B-GP
−/−	O
mice	B-OG
have	O
disrupted	O
central	O
and	O
peripheral	O
kynurenine	O
metabolism	O
(	O
Table	O
1	O
)	O
in	O
a	O
similar	O
pattern	O
to	O
this	O
previous	O
study	O
.	O
39	O
Interestingly	O
,	O
baseline	O
kynurenine	O
levels	O
are	O
significantly	O
elevated	O
in	O
KMO	B-GP
−/−	O
mice	B-OG
without	O
any	O
apparent	O
changes	O
to	O
baseline	O
depressive	O
-	O
like	O
phenotype	O
.	O

This	O
is	O
seemingly	O
in	O
contrast	O
to	O
previous	O
data	O
from	O
our	O
laboratory	O
,	O
and	O
others	O
demonstrating	O
that	O
direct	O
administration	O
of	O
kynurenine	O
can	O
induce	O
deficits	O
in	O
novel	O
object	O
recognition	O
and	O
spatial	O
working	O
memory	O
alter	O
fear	O
conditioning	O
and	O
induce	O
anhedonia	B-DS
.	O
16	O
,	O
33	O
,	O
40	O
,	O
41	O
,	O
42	O
It	O
is	O
possible	O
that	O
the	O
accumulation	O
of	O
kynurenine	O
over	O
time	O
through	O
development	O
allows	O
the	O
system	O
to	O
adjust	O
preventing	O
any	O
potential	O
behavioral	O
changes	O
.	O

Peripheral	O
LPS	O
treatment	O
in	O
KMO	B-GP
−/−	O
mice	B-OG
precipitates	O
an	O
increase	O
in	O
central	O
kynurenine	O
without	O
any	O
changes	O
in	O
central	O
3	O
-	O
HK	O
.	O

The	O
metabolite	O
analyses	O
from	O
HAAO	B-GP
−/−	O
mice	B-OG
(	O
Table	O
1	O
)	O
are	O
the	O
first	O
from	O
a	O
genetic	O
mutant	O
model	O
targeted	O
at	O
this	O
enzyme	O
that	O
metabolizes	O
3	O
-	O
HAA	O
to	O
QA	O
.	O

Although	O
QA	O
was	O
not	O
reliably	O
detected	O
in	O
any	O
brain	O
tissue	O
sample	O
,	O
both	O
central	O
3	O
-	O
HK	O
and	O
3	O
-	O
HAA	O
in	O
HAAO	B-GP
−/−	O
mice	B-OG
were	O
increased	O
over	O
WT	O
levels	O
,	O
as	O
would	O
be	O
predicted	O
in	O
mice	B-OG
lacking	O
the	O
enzyme	O
to	O
metabolize	O
3	O
-	O
HAA	O
to	O
QA	O
.	O

In	O
the	O
plasma	O
,	O
3	O
-	O
HK	O
and	O
3	O
-	O
HAA	O
were	O
similarly	O
elevated	O
in	O
HAAO	B-GP
−/−	O
mice	B-OG
;	O
however	O
,	O
QA	O
was	O
still	O
detectable	O
,	O
indicating	O
the	O
potential	O
for	O
an	O
alternate	O
metabolic	O
source	O
of	O
QA	O
.	O

Although	O
surprising	O
,	O
this	O
peripheral	O
QA	O
is	O
unable	O
to	O
cross	O
the	O
blood	O
–	O
brain	O
barrier	O
and	O
therefore	O
has	O
no	O
direct	O
impact	O
on	O
central	O
QA	O
concentrations	O
and	O
does	O
not	O
contribute	O
to	O
the	O
behavioral	O
phenotype	O
of	O
HAAO	B-GP
−/−	O
mice	B-OG
.	O

It	O
is	O
well	O
accepted	O
that	O
depressive	O
symptoms	O
occur	O
across	O
multiple	O
behavioral	O
domains	O
,	O
and	O
that	O
distinct	O
regions	O
of	O
the	O
brain	O
are	O
critical	O
to	O
each	O
of	O
the	O
various	O
domains	O
of	O
depressive	O
-	O
like	O
behavior	O
.	O

In	O
fact	O
,	O
this	O
is	O
the	O
basic	O
tenet	O
of	O
the	O
National	O
Institute	O
of	O
Mental	O
Health	O
'	O
s	O
(	O
NIMH	O
)	O
Research	O
Domain	O
Criteria	O
(	O
RDoC	O
,	O
http	O
://	O
www	O
.	O
nimh	O
.	O
nih	O
.	O
gov	O
/	O
research	O
-	O
priorities	O
/	O
rdoc	O
/	O
index	O
.	O
shtml	O
)	O
framework	O
to	O
guide	O
mental	O
health	O
research	O
.	O
43	O
,	O
44	O
Preclinical	O
neuropsychiatric	O
research	O
necessarily	O
employs	O
an	O
RDoC	O
framework	O
that	O
deconstructs	O
a	O
behavioral	O
phenotype	O
(	O
neuropsychiatric	B-DS
disorders	I-DS
being	O
modeled	O
)	O
into	O
core	O
behaviors	O
(	O
analogous	O
to	O
symptoms	O
)	O
that	O
are	O
functionally	O
controlled	O
by	O
primary	O
neurocircuits	O
in	O
discrete	O
brain	O
regions	O
.	O

To	O
determine	O
whether	O
increased	O
neurotoxic	O
kynurenine	O
metabolism	O
generates	O
the	O
metabolic	O
substrates	O
to	O
cause	O
the	O
distinct	O
depressive	O
-	O
like	O
behaviors	O
observed	O
in	O
Figures	O
3	O
and	O
5	O
,	O
kynurenine	O
metabolites	O
were	O
measured	O
in	O
the	O
dorsal	O
hippocampus	O
,	O
ventral	O
hippocampus	O
,	O
central	O
amygdala	O
and	O
nucleus	O
accumbens	O
of	O
C57BL6	O
/	O
J	O
mice	B-OG
(	O
Table	O
2	O
),	O
the	O
same	O
background	O
strain	O
of	O
the	O
KMO	B-GP
−/−	O
and	O
HAAO	B-GP
−/−	O
mice	B-OG
,	O
at	O
24	O
h	O
post	O
treatment	O
.	O

These	O
regions	O
were	O
chosen	O
for	O
their	O
relevance	O
to	O
depression	B-DS
in	O
humans	B-OG
as	O
well	O
as	O
the	O
individual	O
behaviors	O
analyzed	O
in	O
this	O
study	O
following	O
peripheral	O
inflammation	O
.	O
45	O
,	O
46	O
,	O
47	O
,	O
48	O
Immobility	O
during	O
the	O
TST	O
and	O
spontaneous	O
alternations	O
in	O
Y	O
-	O
maze	O
are	O
behaviors	O
known	O
to	O
require	O
hippocampal	O
function	O
,	O
and	O
their	O
analogous	O
depressive	O
symptoms	O
are	O
behavioral	O
despair	O
and	O
working	O
memory	O
.	O
49	O
,	O
50	O
,	O
51	O
However	O
,	O
SP	O
requires	O
reward	O
circuitry	O
of	O
the	O
nucleus	O
accumbens	O
,	O
and	O
reduced	O
preference	O
reflects	O
an	O
anhedonia	B-DS
-	O
like	O
phenotype	O
.	O
46	O
Behavior	O
in	O
the	O
OF	O
reflects	O
anxiety	B-DS
-	O
like	O
states	O
that	O
involve	O
amygdala	O
activity	O
.	O
52	O
,	O
53	O

Consistent	O
with	O
previous	O
studies	O
,	O
LPS	O
caused	O
a	O
reduction	O
in	O
circulating	O
tryptophan	O
levels	O
and	O
a	O
robust	O
increase	O
in	O
the	O
concentration	O
of	O
kynurenine	O
in	O
both	O
the	O
periphery	O
and	O
in	O
each	O
brain	O
region	O
analyzed	O
(	O
Tables	O
1	O
and	O
2	O
).	O

However	O
,	O
an	O
interesting	O
pattern	O
was	O
noted	O
in	O
the	O
metabolic	O
profile	O
downstream	O
of	O
kynurenine	O
.	O

Neurotoxic	O
metabolites	O
were	O
generally	O
increased	O
across	O
each	O
brain	O
region	O
,	O
but	O
KA	O
was	O
also	O
significantly	O
increased	O
in	O
central	O
amygdala	O
and	O
nucleus	O
accumbens	O
.	O

Only	O
the	O
dorsal	O
hippocampus	O
reflected	O
a	O
clear	O
shift	O
toward	O
neurotoxic	O
and	O
neuromodulatory	O
(	O
KMO	B-GP
-	O
dependent	O
)	O
metabolism	O
without	O
a	O
parallel	O
increase	O
in	O
the	O
opposing	O
KAT	B-GP
-	O
dependent	O
metabolic	O
branch	O
.	O

The	O
specific	O
behaviors	O
known	O
to	O
involve	O
hippocampal	O
activity	O
were	O
mitigated	O
by	O
genetic	O
inhibition	O
of	O
neurotoxic	O
kynurenine	O
metabolism	O
(	O
in	O
KMO	B-GP
−/−	O
and	O
HAAO	B-GP
−/−	O
mice	B-OG
)	O
and	O
precipitated	O
by	O
direct	O
administration	O
of	O
3	O
-	O
HK	O
.	O

The	O
hippocampus	O
was	O
the	O
only	O
discrete	O
brain	O
region	O
where	O
LPS	O
treatment	O
resulted	O
in	O
a	O
clear	O
and	O
unbalanced	O
shift	O
toward	O
the	O
generation	O
of	O
KMO	B-GP
-	O
dependent	O
metabolites	O
.	O

These	O
findings	O
are	O
consistent	O
with	O
the	O
contemporary	O
hypothesis	O
that	O
disrupting	O
the	O
metabolic	O
balance	O
of	O
the	O
kynurenine	O
pathway	O
,	O
rather	O
than	O
simply	O
increasing	O
overall	O
kynurenine	O
metabolism	O
,	O
defines	O
the	O
functional	O
pathogenic	O
context	O
by	O
which	O
kynurenine	O
metabolism	O
mediates	O
the	O
behavioral	O
effects	O
of	O
inflammation	O
.	O
27	O
,	O
28	O
Further	O
,	O
these	O
data	O
support	O
recent	O
findings	O
from	O
our	O
laboratory	O
,	O
demonstrating	O
that	O
peripheral	O
LPS	O
induces	O
brain	O
region	O
-	O
dependent	O
changes	O
in	O
the	O
balance	O
of	O
kynurenine	O
metabolites	O
,	O
specifically	O
favoring	O
neurotoxic	O
metabolite	O
production	O
in	O
the	O
hippocampus	O
.	O
34	O
Recent	O
data	O
characterizing	O
the	O
regional	O
characteristics	O
of	O
microglia	O
throughout	O
the	O
brain	O
demonstrated	O
that	O
not	O
all	O
microglia	O
express	O
the	O
same	O
functional	O
expression	O
markers	O
.	O
54	O
Specifically	O
,	O
it	O
was	O
noted	O
that	O
microglia	O
in	O
the	O
hippocampus	O
were	O
more	O
responsive	O
to	O
pro	O
-	O
inflammatory	O
stimuli	O
,	O
earning	O
them	O
the	O
label	O
‘	O
immunovigilant	O
'.	O
54	O
This	O
hyper	O
-	O
responsive	O
state	O
of	O
hippocampal	O
microglia	O
could	O
underlie	O
the	O
region	O
-	O
specific	O
elevation	O
in	O
neurotoxic	O
kynurenine	O
metabolism	O
described	O
in	O
Table	O
2	O
.	O

Recent	O
clinical	O
data	O
demonstrated	O
that	O
,	O
following	O
a	O
suicide	O
attempt	O
in	O
depressed	O
patients	O
,	O
CSF	O
QA	O
remains	O
elevated	O
while	O
CSF	O
KA	O
stayed	O
decreased	O
.	O
55	O
In	O
patients	O
with	O
mastocytosis	B-DS
,	O
associated	O
with	O
comorbid	O
depression	B-DS
and	O
inflammation	O
,	O
plasma	O
QA	O
and	O
plasma	O
KA	O
were	O
found	O
to	O
be	O
elevated	O
.	O
56	O
More	O
specifically	O
,	O
in	O
depressed	O
patients	O
,	O
the	O
serum	O
KA	O
/	O
QA	O
ratio	O
(	O
neuroprotective	O
ratio	O
)	O
was	O
positively	O
correlated	O
with	O
increasing	O
volumes	O
of	O
the	O
hippocampus	O
and	O
amygdala	O
.	O
57	O

Previous	O
data	O
in	O
mice	B-OG
with	O
either	O
genetic	O
or	O
systemic	O
inhibition	O
of	O
IDO	B-GP
clearly	O
indicate	O
a	O
pivotal	O
role	O
for	O
kynurenine	O
metabolism	O
in	O
mediating	O
depressive	O
-	O
like	O
behaviors	O
in	O
response	O
to	O
peripheral	O
immune	O
challenge	O
.	O

The	O
general	O
increase	O
in	O
kynurenine	O
metabolism	O
across	O
each	O
brain	O
region	O
(	O
Table	O
2	O
)	O
that	O
was	O
identified	O
in	O
this	O
study	O
supports	O
the	O
conclusions	O
of	O
a	O
broad	O
importance	O
of	O
IDO	B-GP
in	O
mediating	O
the	O
effects	O
of	O
LPS	O
.	O

However	O
,	O
targeting	O
IDO	B-GP
does	O
not	O
provide	O
any	O
indication	O
of	O
which	O
neuroactive	O
downstream	O
metabolites	O
are	O
responsible	O
for	O
driving	O
inflammation	O
-	O
induced	O
behavioral	O
phenotypes	O
.	O

Whereas	O
the	O
previous	O
study	O
by	O
Walker	O
et	O
al	O
.	O
20	O
found	O
that	O
both	O
LPS	O
-	O
induced	O
increases	O
in	O
immobility	O
and	O
reduction	O
in	O
SP	O
could	O
be	O
mitigated	O
by	O
the	O
NMDAR	B-GP
antagonist	O
,	O
ketamine	O
,	O
a	O
direct	O
pathogenic	O
role	O
for	O
QA	O
action	O
on	O
NMDARs	B-GP
can	O
only	O
be	O
speculated	O
.	O
20	O
Here	O
,	O
we	O
provide	O
the	O
first	O
direct	O
evidence	O
that	O
a	O
shift	O
toward	O
neurotoxic	O
metabolism	O
in	O
the	O
hippocampus	O
mediates	O
the	O
behavioral	O
deficits	O
following	O
peripheral	O
LPS	O
.	O

In	O
contrast	O
to	O
the	O
data	O
from	O
Walker	O
et	O
al	O
.,	O
20	O
we	O
found	O
that	O
LPS	O
-	O
induced	O
reductions	O
in	O
SP	O
were	O
not	O
KMO	B-GP
-	O
or	O
HAAO	B-GP
-	O
dependent	O
,	O
as	O
their	O
data	O
suggested	O
.	O

This	O
discrepancy	O
could	O
be	O
the	O
result	O
of	O
strain	O
-	O
related	O
differences	O
in	O
LPS	O
-	O
induced	O
metabolism	O
of	O
CD	O
-	O
1	O
versus	O
C57BL6	O
/	O
J	O
mice	B-OG
,	O
or	O
more	O
likely	O
other	O
neuroactive	O
kynurenines	O
are	O
responsible	O
for	O
driving	O
the	O
LPS	O
-	O
induced	O
anhedonia	B-DS
phenotype	O
,	O
such	O
as	O
XA	O
or	O
KA	O
.	O

It	O
is	O
also	O
possible	O
that	O
the	O
chronic	O
alterations	O
in	O
kynurenine	O
metabolites	O
that	O
exist	O
in	O
the	O
conventional	O
KMO	B-GP
and	O
HAAO	B-GP
null	O
mice	B-OG
results	O
in	O
a	O
compensatory	O
recalibration	O
of	O
the	O
reward	O
system	O
,	O
as	O
the	O
effects	O
of	O
acute	O
and	O
subchronic	O
elevations	O
in	O
KA	O
on	O
the	O
dopaminergic	O
system	O
are	O
well	O
established	O
.	O
58	O
,	O
59	O
Although	O
no	O
baseline	O
differences	O
in	O
SP	O
were	O
observed	O
,	O
it	O
is	O
of	O
interest	O
to	O
note	O
that	O
the	O
LPS	O
-	O
stimulated	O
increase	O
in	O
nucleus	O
accumbens	O
KA	O
could	O
locally	O
decrease	O
extracellular	O
dopamine	O
,	O
similar	O
to	O
a	O
previously	O
demonstrated	O
effect	O
of	O
exogenous	O
KA	O
application	O
to	O
the	O
striatum	O
.	O
60	O
This	O
local	O
reduction	O
in	O
extracellular	O
DA	O
could	O
contribute	O
to	O
the	O
development	O
of	O
anhedonia	B-DS
behavior	O
following	O
LPS	O
treatment	O
.	O

Direct	O
administration	O
of	O
exogenous	O
kynurenine	O
has	O
been	O
utilized	O
in	O
a	O
number	O
of	O
contexts	O
that	O
result	O
in	O
behavioral	O
changes	O
.	O
40	O
,	O
41	O
,	O
59	O
Our	O
previous	O
work	O
demonstrated	O
that	O
exogenous	O
kynurenine	O
acutely	O
precipitates	O
a	O
depressive	O
-	O
like	O
phenotype	O
similar	O
to	O
LPS	O
.	O
16	O
Chronic	O
administration	O
of	O
kynurenine	O
during	O
early	O
development	O
or	O
to	O
adult	O
mice	B-OG
has	O
also	O
been	O
used	O
to	O
elevate	O
KA	O
levels	O
in	O
the	O
brain	O
,	O
resulting	O
in	O
deficits	O
in	O
sensorimotor	O
gating	O
,	O
attentional	O
processing	O
of	O
environmental	O
stimuli	O
,	O
spatial	O
working	O
memory	O
and	O
contextual	O
learning	O
memory	O
.	O
40	O
,	O
41	O
,	O
61	O
The	O
data	O
here	O
are	O
the	O
first	O
to	O
demonstrate	O
that	O
exogenously	O
administered	O
peripheral	O
3	O
-	O
HK	O
is	O
able	O
to	O
precipitate	O
the	O
development	O
of	O
behavioral	O
despair	O
in	O
the	O
TST	O
,	O
impair	O
working	O
memory	O
in	O
the	O
Y	O
-	O
maze	O
and	O
induce	O
anxiety	B-DS
-	O
like	O
behavior	O
assessed	O
in	O
the	O
OF	O
.	O

Of	O
note	O
,	O
general	O
locomotor	O
activity	O
in	O
the	O
OF	O
(	O
Supplementary	O
Figure	O
1A	O
,	O
1C	O
),	O
although	O
confirmatory	O
of	O
a	O
positive	O
effect	O
of	O
LPS	O
,	O
was	O
not	O
correlated	O
to	O
depressive	O
-	O
like	O
behaviors	O
in	O
any	O
of	O
the	O
testing	O
paradigms	O
.	O

This	O
effect	O
of	O
LPS	O
in	O
the	O
OF	O
is	O
similar	O
to	O
previously	O
published	O
data	O
from	O
our	O
laboratory	O
,	O
demonstrating	O
that	O
duration	O
in	O
the	O
central	O
area	O
(	O
anxiety	B-DS
-	O
like	O
behavior	O
)	O
does	O
not	O
depend	O
on	O
locomotor	O
activity	O
.	O
16	O
Although	O
the	O
open	O
was	O
conducted	O
under	O
low	O
-	O
light	O
conditions	O
and	O
more	O
light	O
might	O
provide	O
a	O
greater	O
ethological	O
conflict	O
for	O
assessing	O
anxiety	B-DS
-	O
like	O
behavior	O
,	O
the	O
primary	O
purpose	O
of	O
this	O
assessment	O
was	O
to	O
determine	O
the	O
impact	O
of	O
treatment	O
on	O
locomotor	O
activity	O
.	O

Together	O
,	O
these	O
data	O
significantly	O
enhance	O
our	O
understanding	O
of	O
the	O
metabolic	O
substrates	O
that	O
mediate	O
inflammation	O
-	O
induced	O
depressive	O
-	O
like	O
behavior	O
.	O

Whereas	O
a	O
majority	O
of	O
brain	O
kynurenine	O
is	O
supplied	O
by	O
the	O
circulation	O
,	O
62	O
these	O
data	O
indicate	O
that	O
downstream	O
metabolism	O
is	O
a	O
regionally	O
regulated	O
process	O
with	O
implications	O
for	O
behavioral	O
pathology	O
.	O

Our	O
data	O
indicate	O
that	O
hippocampal	O
-	O
dependent	O
behaviors	O
may	O
be	O
particularly	O
vulnerable	O
to	O
neurotoxic	O
dysregulation	O
of	O
kynurenine	O
metabolism	O
,	O
which	O
could	O
also	O
have	O
larger	O
implications	O
in	O
the	O
context	O
of	O
neurodegenerative	B-DS
disease	I-DS
and	O
chronic	B-DS
inflammatory	I-DS
conditions	I-DS
.	O

Therapeutic	O
manipulation	O
of	O
the	O
kynurenine	O
metabolic	O
pathway	O
remains	O
a	O
potentially	O
valuable	O
strategy	O
for	O
alleviating	O
depressive	O
symptoms	O
,	O
particularly	O
in	O
the	O
context	O
of	O
inflammation	O
and	O
comorbidity	O
.	O

Supplementary	O
Information	O
accompanies	O
the	O
paper	O
on	O
the	O
Translational	O
Psychiatry	O
website	O
(	O
http	O
://	O
www	O
.	O
nature	O
.	O
com	O
/	O
tp	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

The	O
kynurenine	O
pathway	O
of	O
tryptophan	O
metabolism	O
.	O

In	O
the	O
kynurenine	O
pathway	O
,	O
tryptophan	O
is	O
metabolized	O
to	O
kynurenine	O
by	O
indoleamine	B-GP
2	I-GP
,	I-GP
3	I-GP
-	I-GP
dioxygenase	I-GP
(	O
IDO	B-GP
),	O
an	O
enzyme	O
that	O
is	O
upregulated	O
by	O
pro	B-GP
-	I-GP
inflammatory	I-GP
cytokines	I-GP
.	O

Kynurenine	O
is	O
then	O
either	O
metabolized	O
to	O
kynurenic	O
acid	O
(	O
KA	O
)	O
by	O
kynurenine	B-GP
aminotransferases	I-GP
(	O
KATs	B-GP
),	O
or	O
to	O
3	O
-	O
hydroxykynurenine	O
(	O
3	O
-	O
HK	O
,	O
red	O
)	O
by	O
kynurenine	B-GP
-	I-GP
3	I-GP
-	I-GP
monooxygenase	I-GP
(	O
KMO	B-GP
,	O
purple	O
).	O

Under	O
basal	O
conditions	O
,	O
most	O
of	O
kynurenine	O
in	O
the	O
brain	O
is	O
metabolized	O
to	O
KA	O
,	O
a	O
N	O
-	O
methyl	O
-	O
D	O
-	O
aspartate	O
(	O
NMDA	O
)	O
and	O
α7	B-GP
-	I-GP
nicotinic	I-GP
acetylcholine	I-GP
(	I-GP
α7nACh	I-GP
)	I-GP
receptor	I-GP
antagonist	O
.	O

However	O
,	O
neuroinflammation	O
and	O
pro	B-GP
-	I-GP
inflammatory	I-GP
cytokines	I-GP
will	O
shift	O
kynurenine	O
metabolism	O
through	O
KMO	B-GP
to	O
3	O
-	O
HK	O
.	O

Then	O
,	O
further	O
metabolism	O
occurs	O
to	O
3	O
-	O
hydroxyanthranilic	O
acid	O
(	O
3	O
-	O
HAA	O
)	O
by	O
kynureninase	B-GP
(	O
KYNU	B-GP
),	O
and	O
then	O
3	O
-	O
HAA	O
is	O
metabolized	O
to	O
quinolinic	O
acid	O
(	O
QA	O
,	O
red	O
)	O
by	O
3	B-GP
-	I-GP
hydroxyanthranilic	I-GP
acid	I-GP
dioxygenase	I-GP
(	O
HAAO	B-GP
,	O
purple	O
).	O

During	O
neuroinflammation	O
,	O
QA	O
is	O
the	O
major	O
end	O
product	O
of	O
the	O
kynurenine	O
pathway	O
,	O
a	O
metabolite	O
that	O
is	O
a	O
NMDA	B-GP
receptor	I-GP
agonist	O
and	O
an	O
oxidative	O
stressor	O
.	O

3	O
-	O
HK	O
can	O
also	O
be	O
metabolized	O
to	O
xanthurenic	O
acid	O
(	O
XA	O
)	O
by	O
KATs	B-GP
when	O
substrate	O
levels	O
are	O
high	O
enough	O
.	O

This	O
branch	O
of	O
metabolites	O
(	O
3	O
-	O
HK	O
,	O
3	O
-	O
HAA	O
,	O
QA	O
,	O
XA	O
)	O
is	O
considered	O
to	O
be	O
neurotoxic	O
(	O
orange	O
box	O
)	O
as	O
they	O
can	O
contribute	O
to	O
oxidative	O
stress	O
and	O
glutamate	O
excitotoxicity	O
.	O

In	O
the	O
studies	O
described	O
,	O
two	O
genetic	O
mouse	B-OG
models	O
were	O
used	O
(	O
KMO	B-GP
and	O
HAAO	B-GP
knockouts	O
)	O
to	O
target	O
neurotoxic	O
kynurenine	O
metabolism	O
(	O
indicated	O
by	O
purple	O
‘	O
no	O
'	O
symbol	O
).	O

Kynurenine	B-GP
3	I-GP
-	I-GP
monooxygenase	I-GP
(	O
KMO	B-GP
)	O
and	O
3	B-GP
-	I-GP
hydroxyanthranilic	I-GP
acid	I-GP
dioxygenase	I-GP
(	O
HAAO	B-GP
)	O
transgene	O
construct	O
.	O

(	O
a	O
)	O
The	O
KMO	B-GP
transgene	O
vector	O
was	O
designed	O
with	O
a	O
neomycin	O
(	O
neo	O
)	O
selection	O
cassette	O
to	O
test	O
for	O
site	O
-	O
specific	O
integration	O
of	O
the	O
transgene	O
.	O

Proper	O
incorporation	O
of	O
the	O
transgene	O
results	O
in	O
gene	O
-	O
trapping	O
between	O
the	O
reporter	O
gene	O
(	O
lacZ	B-GP
)	O
from	O
the	O
cassette	O
and	O
the	O
Kmo	B-GP
gene	O
during	O
transcription	O
.	O

When	O
these	O
transcripts	O
become	O
spliced	O
together	O
,	O
an	O
insertion	O
mutation	O
is	O
created	O
resulting	O
in	O
a	O
non	O
-	O
functional	O
KMO	B-GP
protein	O
and	O
a	O
KMO	B-GP
−/−	O
mouse	B-OG
.	O

The	O
vector	O
also	O
includes	O
recombination	O
sites	O
(	O
Flp	O
recombination	O
target	O
(	O
FRT	O
),	O
loxP	O
)	O
that	O
can	O
be	O
used	O
to	O
create	O
a	O
conditional	O
-	O
ready	O
mouse	B-OG
targeted	O
for	O
the	O
gene	O
of	O
interest	O
(	O
that	O
is	O
,	O
KMO	B-GP
-	O
floxed	O
).	O

(	O
b	O
)	O
The	O
presence	O
of	O
the	O
transgene	O
in	O
KMO	B-GP
transgenic	O
mice	B-OG
were	O
confirmed	O
using	O
RT	O
-	O
PCR	O
for	O
either	O
the	O
wild	O
-	O
type	O
allele	O
(	O
476	O
-	O
bp	O
band	O
)	O
or	O
the	O
transgenic	O
allele	O
(	O
592	O
-	O
bp	O
band	O
),	O
as	O
indicated	O
in	O
a	O
.	O

(	O
c	O
)	O
The	O
HAAO	B-GP
transgene	O
vector	O
was	O
designed	O
identical	O
to	O
the	O
KMO	B-GP
transgene	O
(	O
a	O
),	O
targeting	O
the	O
HAAO	B-GP
genetic	O
sequence	O
.	O

(	O
d	O
)	O
The	O
presence	O
of	O
the	O
HAAO	B-GP
transgene	O
was	O
confirmed	O
in	O
the	O
same	O
manner	O
as	O
the	O
KMO	B-GP
transgene	O
using	O
a	O
RT	O
-	O
PCR	O
reaction	O
for	O
the	O
wild	O
-	O
type	O
allele	O
(	O
516	O
bp	O
)	O
and	O
for	O
the	O
transgenic	O
allele	O
(	O
594	O
bp	O
).	O

Kynurenine	B-GP
3	I-GP
-	I-GP
monooxygenase	I-GP
(	O
KMO	B-GP
)	O
knockout	O
mice	B-OG
are	O
protected	O
from	O
distinct	O
inflammation	O
-	O
induced	O
depressive	O
-	O
like	O
behaviors	O
.	O

(	O
a	O
)	O
Twenty	O
-	O
four	O
hours	O
following	O
injection	O
with	O
either	O
lipopolysaccharide	O
(	O
LPS	O
)	O
or	O
saline	O
,	O
wild	O
type	O
(	O
WT	O
)	O
and	O
KMO	B-GP
−/−	O
mice	B-OG
were	O
tested	O
in	O
the	O
tail	O
suspension	O
test	O
(	O
TST	O
)	O
to	O
assess	O
behavioral	O
despair	O
.	O

LPS	O
increases	O
duration	O
spent	O
immobile	O
(	O
seconds	O
,	O
represented	O
as	O
%	O
Saline	O
)	O
in	O
WT	O
mice	B-OG
but	O
not	O
in	O
KMO	B-GP
−/−	O
mice	B-OG
.	O

(	O
b	O
)	O
Sucrose	O
and	O
water	O
intake	O
were	O
recorded	O
for	O
the	O
24h	O
following	O
LPS	O
or	O
saline	O
injections	O
and	O
were	O
used	O
to	O
calculate	O
sucrose	O
preference	O
(	O
SP	O
)	O
to	O
assess	O
anhedonia	B-DS
-	O
like	O
behavior	O
.	O

LPS	O
treatment	O
resulted	O
in	O
a	O
characteristic	O
reduction	O
in	O
SP	O
in	O
both	O
WT	O
and	O
KMO	B-GP
−/−	O
mice	B-OG
.	O

(	O
c	O
)	O
Similarly	O
,	O
at	O
24	O
h	O
post	O
treatment	O
,	O
duration	O
(	O
seconds	O
,	O
represented	O
as	O
%	O
Saline	O
)	O
in	O
the	O
center	O
of	O
the	O
open	O
field	O
(	O
OF	O
)	O
was	O
recorded	O
as	O
an	O
index	O
of	O
anxiety	B-DS
-	O
like	O
behavior	O
.	O

(	O
d	O
)	O
Duration	O
spent	O
near	O
the	O
walls	O
of	O
the	O
OF	O
or	O
thigmotaxis	O
behavior	O
(	O
seconds	O
,	O
represented	O
as	O
%	O
Saline	O
)	O
was	O
also	O
recorded	O
to	O
asses	O
anxiety	B-DS
-	O
like	O
behavior	O
.	O

In	O
both	O
OF	O
assessments	O
(	O
c	O
,	O
d	O
),	O
LPS	O
treatment	O
resulted	O
in	O
similar	O
elevations	O
in	O
anxiety	B-DS
-	O
like	O
behavior	O
in	O
WT	O
and	O
KMO	B-GP
−/−	O
mice	B-OG
.	O

(	O
e	O
)	O
Spontaneous	O
alterations	O
(	O
represented	O
as	O
%	O
Saline	O
)	O
between	O
the	O
three	O
arms	O
of	O
a	O
Y	O
-	O
maze	O
were	O
recorded	O
as	O
an	O
index	O
of	O
working	O
memory	O
.	O

LPS	O
treatment	O
resulted	O
in	O
a	O
significant	O
deficit	O
in	O
spontaneous	O
alterations	O
in	O
WT	O
mice	B-OG
but	O
KMO	B-GP
−/−	O
mice	B-OG
were	O
unaffected	O
.	O

Data	O
represent	O
sample	O
means	O
±	O
s	O
.	O
e	O
.	O
m	O
.	O
n	O
=	O
13	O
–	O
29	O
mice	B-OG
per	O
group	O
.	O
*	O
Main	O
effect	O
or	O
post	O
hoc	O
comparison	O
between	O
saline	O
and	O
LPS	O
within	O
the	O
same	O
genotype	O
.	O
+	O
Post	O
hoc	O
comparison	O
to	O
WT	O
with	O
the	O
same	O
intraperitoneal	O
(	O
i	O
.	O
p	O
.)	O
treatment	O
.	O
*,+	O
P	O
<	O
0	O
.	O
05	O
–	O
0	O
.	O
01	O
;	O
**,++	O
P	O
<	O
0	O
.	O
01	O
–	O
0	O
.	O
001	O
;	O
***,+++	O
P	O
<	O
0	O
.	O
001	O
.	O

3	O
-	O
Hydroxykynurenine	O
(	O
3	O
-	O
HK	O
)	O
administration	O
induces	O
behavioral	O
despair	O
and	O
working	O
memory	B-DS
deficits	I-DS
.	O

(	O
a	O
)	O
The	O
metabolite	O
produced	O
by	O
kynurenine	B-GP
3	I-GP
-	I-GP
monooxygenase	I-GP
(	O
KMO	B-GP
),	O
3	O
-	O
HK	O
,	O
was	O
injected	O
subcutaneously	O
30	O
min	O
before	O
assessing	O
behavioral	O
despair	O
in	O
the	O
tail	O
suspension	O
test	O
(	O
TST	O
).	O

3	O
-	O
HK	O
was	O
administered	O
at	O
doses	O
of	O
0	O
.	O
0	O
mg	O
kg	O
−	O
1	O
(	O
vehicle	O
),	O
3	O
.	O
33	O
and	O
10	O
mg	O
kg	O
−	O
1	O
and	O
resulted	O
in	O
an	O
increased	O
immobile	O
duration	O
(	O
seconds	O
,	O
represented	O
as	O
%	O
Vehicle	O
).	O

(	O
b	O
)	O
Sucrose	O
preference	O
(	O
SP	O
)	O
was	O
measured	O
2	O
h	O
beginning	O
30	O
min	O
post	O
-	O
subcutaneous	O
3	O
-	O
HK	O
administration	O
(	O
0	O
.	O
0	O
mg	O
kg	O
−	O
1	O
(	O
vehicle	O
),	O
3	O
.	O
33	O
and	O
10	O
mg	O
kg	O
−	O
1	O
),	O
and	O
anhedonia	B-DS
-	O
like	O
behavior	O
was	O
unaffected	O
by	O
peripheral	O
3	O
-	O
HK	O
.	O

Thirty	O
minutes	O
following	O
3	O
-	O
HK	O
subcutaneous	O
administration	O
(	O
0	O
.	O
0	O
mg	O
kg	O
−	O
1	O
(	O
vehicle	O
),	O
3	O
.	O
33	O
and	O
10	O
mg	O
kg	O
−	O
1	O
),	O
activity	O
was	O
recorded	O
in	O
the	O
open	O
field	O
(	O
OF	O
)	O
to	O
determine	O
anxiety	B-DS
-	O
like	O
behavior	O
.	O

3	O
-	O
HK	O
decreased	O
the	O
duration	O
(	O
seconds	O
,	O
represented	O
as	O
%	O
Vehicle	O
;	O
(	O
c	O
)	O
in	O
the	O
center	O
of	O
the	O
OF	O
while	O
there	O
was	O
no	O
impact	O
of	O
3	O
-	O
HK	O
on	O
(	O
d	O
)	O
thigmotoxis	O
behavior	O
.	O

Working	O
memory	O
was	O
also	O
assessed	O
in	O
the	O
Y	O
-	O
maze	O
30	O
min	O
following	O
subcutaneous	O
administration	O
(	O
0	O
.	O
0	O
mg	O
kg	O
−	O
1	O
(	O
vehicle	O
),	O
3	O
.	O
33	O
and	O
10	O
mg	O
kg	O
−	O
1	O
)	O
of	O
3	O
-	O
HK	O
.	O

(	O
e	O
)	O
Spontaneous	O
alterations	O
(%	O
Vehicle	O
)	O
decreased	O
following	O
treatment	O
with	O
3	O
-	O
HK	O
.	O

(	O
f	O
)	O
Plasma	O
3	O
-	O
HK	O
concentrations	O
(	O
μM	O
)	O
increased	O
following	O
administration	O
of	O
3	O
-	O
HK	O
.	O

(	O
g	O
)	O
Similarly	O
,	O
3	O
-	O
HK	O
(	O
μM	O
)	O
assessed	O
in	O
brain	O
tissue	O
was	O
elevated	O
by	O
peripheral	O
3	O
-	O
HK	O
treatment	O
.	O

Data	O
represent	O
sample	O
means	O
±	O
s	O
.	O
e	O
.	O
m	O
.	O
n	O
=	O
5	O
-	O
16	O
mice	B-OG
per	O
group	O
.	O
*	O
Main	O
effect	O
or	O
post	O
hoc	O
comparison	O
to	O
saline	O
or	O
vehicle	O
.	O
*	O
P	O
<	O
0	O
.	O
05	O
–	O
0	O
.	O
01	O
;	O
**	O
P	O
<	O
0	O
.	O
01	O
–	O
0	O
.	O
001	O
;	O
***	O
P	O
<	O
0	O
.	O
001	O
.	O

3	B-GP
-	I-GP
Hydroxyanthranilic	I-GP
acid	I-GP
dioxygenase	I-GP
(	O
HAAO	B-GP
)	O
transgenic	O
mice	B-OG
are	O
shielded	O
from	O
inflammation	O
-	O
induced	O
behavioral	O
despair	O
.	O

(	O
a	O
)	O
HAAO	B-GP
−/−	O
or	O
wild	O
-	O
type	O
(	O
WT	O
)	O
mice	B-OG
were	O
assessed	O
for	O
duration	O
spent	O
immobile	O
(	O
s	O
)	O
in	O
the	O
TST	O
24	O
h	O
following	O
lipopolysaccharide	O
(	O
LPS	O
)	O
or	O
saline	O
injections	O
.	O

Whereas	O
LPS	O
treatment	O
increased	O
immobile	O
duration	O
(	O
represented	O
as	O
%	O
Saline	O
)	O
in	O
WT	O
mice	B-OG
,	O
HAAO	B-GP
−/−	O
mice	B-OG
were	O
protected	O
from	O
this	O
LPS	O
-	O
induced	O
change	O
in	O
behavior	O
.	O

(	O
b	O
)	O
Following	O
LPS	O
treatment	O
,	O
both	O
WT	O
and	O
HAAO	B-GP
−/−	O
mice	B-OG
had	O
a	O
reduction	O
in	O
sucrose	O
preference	O
(	O
SP	O
)	O
representing	O
anhedonia	B-DS
-	O
like	O
behavior	O
.	O

(	O
c	O
)	O
In	O
addition	O
,	O
behavior	O
in	O
the	O
open	O
field	O
(	O
OF	O
)	O
was	O
analyzed	O
for	O
the	O
effect	O
of	O
LPS	O
treatment	O
on	O
duration	O
spent	O
in	O
the	O
center	O
of	O
the	O
arena	O
(	O
represented	O
as	O
%	O
Saline	O
),	O
an	O
index	O
of	O
anxiety	B-DS
-	O
like	O
behavior	O
.	O

LPS	O
reduced	O
time	O
spent	O
in	O
the	O
central	O
area	O
similarly	O
in	O
both	O
genotypes	O
.	O

(	O
d	O
)	O
Further	O
,	O
thigmotaxis	O
(	O
duration	O
)	O
was	O
extracted	O
from	O
the	O
OF	O
behavior	O
(	O
represented	O
as	O
%	O
Saline	O
),	O
which	O
was	O
increased	O
by	O
LPS	O
treatment	O
both	O
in	O
WT	O
and	O
HAAO	B-GP
−/−	O
mice	B-OG
.	O

(	O
e	O
)	O
Spontaneous	O
alternations	O
(	O
represented	O
as	O
%	O
Saline	O
)	O
in	O
a	O
Y	O
-	O
maze	O
,	O
an	O
assessment	O
of	O
working	O
memory	O
,	O
were	O
reduced	O
by	O
LPS	O
treatment	O
only	O
in	O
WT	O
mice	B-OG
and	O
not	O
in	O
HAAO	B-GP
−/−	O
mice	B-OG
.	O

Data	O
represent	O
sample	O
means	O
±	O
s	O
.	O
e	O
.	O
m	O
.	O
and	O
were	O
analyzed	O
using	O
a	O
two	O
-	O
analysis	O
of	O
variance	O
(	O
ANOVA	O
),	O
followed	O
by	O
the	O
Holm	O
–	O
Sidak	O
method	O
for	O
pairwise	O
multiple	O
comparisons	O
.	O
n	O
=	O
11	O
–	O
22	O
mice	B-OG
per	O
group	O
.	O
*	O
Main	O
effect	O
or	O
post	O
hoc	O
comparison	O
between	O
saline	O
and	O
LPS	O
within	O
the	O
same	O
genotype	O
.	O
+	O
Post	O
hoc	O
comparison	O
to	O
WT	O
with	O
the	O
same	O
intraperitoneal	O
(	O
i	O
.	O
p	O
.)	O
treatment	O
.	O
*,+	O
P	O
<	O
0	O
.	O
05	O
–	O
0	O
.	O
01	O
;	O
**,++	O
P	O
<	O
0	O
.	O
01	O
–	O
0	O
.	O
001	O
;	O
***,+++	O
P	O
<	O
0	O
.	O
001	O
.	O


Genotype	O

Main	O
effects	O

Interaction	O


WT	O

KMO	B-GP
−/−	O

HAAO	B-GP
−/−	O

Treatment	O
P	O
-	O
value	O

Genotype	O
P	O
-	O
value	O

Treatment	O
×	O
genotype	O


Saline	O

LPS	O

Saline	O

LPS	O

Saline	O

LPS	O




Brain	O
metabolites	O
(	O
μM	O
)	O

Tryptophan	O

31	O
.	O
20	O
(	O
2	O
.	O
1	O
)	O

34	O
.	O
44	O
(	O
2	O
.	O
9	O
)	O

37	O
.	O
54	O
(	O
8	O
.	O
0	O
)	O

45	O
.	O
25	O
(	O
8	O
.	O
0	O
)	O

55	O
.	O
49	O
(	O
3	O
.	O
3	O
)	O

67	O
.	O
96	O
(	O
0	O
.	O
9	O
)	O

P	O
<	O
0	O
.	O
05	O

P	O
<	O
0	O
.	O
001	O

n	O
.	O
s	O
.	O

Kynurenine	O

0	O
.	O
17	O
(	O
0	O
.	O
01	O
)	O

0	O
.	O
59	O
(	O
0	O
.	O
06	O
)**	O

2	O
.	O
95	O
(	O
0	O
.	O
2	O
)+++	O

3	O
.	O
82	O
(	O
0	O
.	O
3	O
)***,+++	O

0	O
.	O
32	O
(	O
0	O
.	O
05	O
)	O

2	O
.	O
02	O
(	O
0	O
.	O
1	O
)***,+++	O

P	O
<	O
0	O
.	O
001	O

P	O
<	O
0	O
.	O
001	O

P	O
<	O
0	O
.	O
001	O

3	O
-	O
HK	O

0	O
.	O
044	O
(	O
0	O
.	O
007	O
)	O

0	O
.	O
17	O
(	O
0	O
.	O
03	O
)***	O

n	O
.	O
d	O
.	O

n	O
.	O
d	O
.	O

0	O
.	O
54	O
(	O
0	O
.	O
2	O
)	O

0	O
.	O
51	O
(	O
0	O
.	O
08	O
)	O

n	O
/	O
a	O

n	O
/	O
a	O

n	O
/	O
a	O

3	O
-	O
HAA	O

0	O
.	O
29	O
(	O
0	O
.	O
06	O
)	O

0	O
.	O
25	O
(	O
0	O
.	O
04	O
)	O

0	O
.	O
26	O
(	O
0	O
.	O
03	O
)	O

0	O
.	O
12	O
(	O
0	O
.	O
04	O
)	O

0	O
.	O
99	O
(	O
0	O
.	O
07	O
)+++	O

0	O
.	O
44	O
(	O
0	O
.	O
05	O
)***,++	O

P	O
<	O
0	O
.	O
001	O

P	O
<	O
0	O
.	O
001	O

P	O
<	O
0	O
.	O
001	O

QA	O

n	O
.	O
d	O
.	O

n	O
.	O
d	O
.	O

n	O
.	O
d	O
.	O

n	O
.	O
d	O
.	O

n	O
.	O
d	O
.	O

n	O
.	O
d	O
.	O

n	O
/	O
a	O

n	O
/	O
a	O

n	O
/	O
a	O

KA	O

0	O
.	O
12	O
(	O
0	O
.	O
04	O
)	O

0	O
.	O
10	O
(	O
0	O
.	O
02	O
)	O

0	O
.	O
37	O
(	O
0	O
.	O
08	O
)	O

0	O
.	O
31	O
(	O
0	O
.	O
05	O
)	O

0	O
.	O
021	O
(	O
0	O
.	O
002	O
)	O

0	O
.	O
038	O
(	O
0	O
.	O
001	O
)	O

n	O
.	O
s	O
.	O

P	O
<	O
0	O
.	O
001	O

n	O
.	O
s	O
.	O


Plasma	O
metabolites	O
(	O
μM	O
)	O

Tryptophan	O

96	O
.	O
00	O
(	O
4	O
.	O
7	O
)	O

78	O
.	O
36	O
(	O
7	O
.	O
4	O
)	O

65	O
.	O
72	O
(	O
3	O
.	O
9	O
)	O

49	O
.	O
39	O
(	O
2	O
.	O
6	O
)	O

120	O
.	O
62	O
(	O
9	O
.	O
5	O
)	O

98	O
.	O
23	O
(	O
3	O
.	O
0	O
)	O

P	O
<	O
0	O
.	O
05	O

P	O
<	O
0	O
.	O
001	O

n	O
.	O
s	O
.	O

Kynurenine	O

0	O
.	O
80	O
(	O
0	O
.	O
06	O
)	O

2	O
.	O
41	O
(	O
0	O
.	O
1	O
)	O

11	O
.	O
13	O
(	O
2	O
.	O
0	O
)	O

9	O
.	O
86	O
(	O
0	O
.	O
3	O
)	O

0	O
.	O
88	O
(	O
0	O
.	O
08	O
)	O

3	O
.	O
19	O
(	O
0	O
.	O
4	O
)	O

n	O
.	O
s	O
.	O

P	O
<	O
0	O
.	O
001	O

n	O
.	O
s	O
.	O

3	O
-	O
HK	O

0	O
.	O
083	O
(	O
0	O
.	O
01	O
)	O

0	O
.	O
45	O
(	O
0	O
.	O
03	O
)***	O

0	O
.	O
0098	O
(	O
0	O
.	O
002	O
)	O

0	O
.	O
017	O
(	O
0	O
.	O
006	O
)+++	O

0	O
.	O
13	O
(	O
0	O
.	O
02	O
)	O

0	O
.	O
87	O
(	O
0	O
.	O
08	O
)***,+++	O

P	O
<	O
0	O
.	O
001	O

P	O
<	O
0	O
.	O
001	O

P	O
<	O
0	O
.	O
001	O

3	O
-	O
HAA	O

n	O
.	O
d	O
.	O

n	O
.	O
d	O
.	O

n	O
.	O
d	O
.	O

n	O
.	O
d	O
.	O

2	O
.	O
17	O
(	O
0	O
.	O
27	O
)	O

3	O
.	O
16	O
(	O
1	O
.	O
0	O
)	O

n	O
/	O
a	O

n	O
/	O
a	O

n	O
/	O
a	O

QA	O

0	O
.	O
39	O
(	O
0	O
.	O
03	O
)	O

0	O
.	O
48	O
(	O
0	O
.	O
08	O
)	O

0	O
.	O
24	O
(	O
0	O
.	O
008	O
)	O

0	O
.	O
30	O
(	O
0	O
.	O
004	O
)	O

0	O
.	O
64	O
(	O
0	O
.	O
04	O
)	O

0	O
.	O
58	O
(	O
0	O
.	O
02	O
)	O

n	O
.	O
s	O
.	O

P	O
<	O
0	O
.	O
001	O

n	O
.	O
s	O
.	O

KA	O

0	O
.	O
94	O
(	O
0	O
.	O
1	O
)	O

0	O
.	O
59	O
(	O
0	O
.	O
07	O
)	O

31	O
.	O
45	O
(	O
5	O
.	O
3	O
)+++	O

15	O
.	O
78	O
(	O
0	O
.	O
8	O
)***,+++	O

0	O
.	O
24	O
(	O
0	O
.	O
04	O
)	O

0	O
.	O
21	O
(	O
0	O
.	O
02	O
)	O

P	O
<	O
0	O
.	O
001	O

P	O
<	O
0	O
.	O
001	O

P	O
<	O
0	O
.	O
001	O

Brain	O
region	O

Metabolite	O
(	O
μM	O
)	O

Treatment	O
(	O
i	O
.	O
p	O
.)	O

t	O
-	O
Test	O
,	O
P	O
-	O
value	O



Saline	O

LPS	O


Dorsal	O
hippocampus	O

Tryptophan	O

102	O
.	O
93	O
(	O
5	O
.	O
1	O
)	O

129	O
.	O
83	O
(	O
4	O
.	O
1	O
)***	O

P	O
<	O
0	O
.	O
001	O


Kynurenine	O

0	O
.	O
39	O
(	O
0	O
.	O
03	O
)	O

1	O
.	O
02	O
(	O
0	O
.	O
1	O
)***	O

P	O
<	O
0	O
.	O
001	O


3	O
-	O
HK	O

0	O
.	O
13	O
(	O
0	O
.	O
01	O
)	O

0	O
.	O
19	O
(	O
0	O
.	O
02	O
)*	O

P	O
<	O
0	O
.	O
05	O


3	O
-	O
HAA	O

1	O
.	O
35	O
(	O
0	O
.	O
06	O
)	O

1	O
.	O
86	O
(	O
0	O
.	O
1	O
)**	O

P	O
<	O
0	O
.	O
01	O


KA	O

0	O
.	O
095	O
(	O
0	O
.	O
02	O
)	O

0	O
.	O
13	O
(	O
0	O
.	O
02	O
)	O

n	O
.	O
s	O
.	O


XA	O

0	O
.	O
0085	O
(	O
0	O
.	O
001	O
)	O

0	O
.	O
023	O
(	O
0	O
.	O
003	O
)**	O

P	O
<	O
0	O
.	O
01	O






Ventral	O
hippocampus	O

Tryptophan	O

95	O
.	O
38	O
(	O
4	O
.	O
5	O
)	O

122	O
.	O
83	O
(	O
9	O
.	O
2	O
)	O

n	O
.	O
s	O
.	O


Kynurenine	O

0	O
.	O
33	O
(	O
0	O
.	O
04	O
)	O

0	O
.	O
85	O
(	O
0	O
.	O
04	O
)***	O

P	O
<	O
0	O
.	O
001	O


3	O
-	O
HK	O

0	O
.	O
12	O
(	O
0	O
.	O
02	O
)	O

0	O
.	O
15	O
(	O
0	O
.	O
02	O
)	O

n	O
.	O
s	O
.	O


3	O
-	O
HAA	O

1	O
.	O
62	O
(	O
0	O
.	O
08	O
)	O

1	O
.	O
60	O
(	O
0	O
.	O
2	O
)	O

n	O
.	O
s	O
.	O


KA	O

0	O
.	O
12	O
(	O
0	O
.	O
01	O
)	O

0	O
.	O
14	O
(	O
0	O
.	O
03	O
)	O

n	O
.	O
s	O
.	O


XA	O

0	O
.	O
012	O
(	O
0	O
.	O
001	O
)	O

0	O
.	O
024	O
(	O
0	O
.	O
003	O
)*	O

P	O
<	O
0	O
.	O
05	O






Central	O
amygdala	O

Tryptophan	O

119	O
.	O
34	O
(	O
5	O
.	O
7	O
)	O

218	O
.	O
78	O
(	O
17	O
.	O
0	O
)***	O

P	O
<	O
0	O
.	O
001	O


Kynurenine	O

0	O
.	O
46	O
(	O
0	O
.	O
04	O
)	O

1	O
.	O
60	O
(	O
0	O
.	O
1	O
)***	O

P	O
<	O
0	O
.	O
001	O


3	O
-	O
HK	O

0	O
.	O
11	O
(	O
0	O
.	O
01	O
)	O

0	O
.	O
19	O
(	O
0	O
.	O
03	O
)*	O

P	O
<	O
0	O
.	O
05	O


3	O
-	O
HAA	O

n	O
.	O
d	O
.	O

n	O
.	O
d	O
.	O

n	O
/	O
a	O


KA	O

0	O
.	O
12	O
(	O
0	O
.	O
02	O
)	O

0	O
.	O
40	O
(	O
0	O
.	O
1	O
)*	O

P	O
<	O
0	O
.	O
05	O


XA	O

0	O
.	O
0076	O
(	O
0	O
.	O
002	O
)	O

0	O
.	O
015	O
(	O
0	O
.	O
002	O
)**	O

P	O
<	O
0	O
.	O
01	O






Nucleus	O
accumbens	O

Tryptophan	O

112	O
.	O
82	O
(	O
9	O
.	O
8	O
)	O

167	O
.	O
35	O
(	O
19	O
.	O
3	O
)*	O

P	O
<	O
0	O
.	O
05	O


Kynurenine	O

0	O
.	O
45	O
(	O
0	O
.	O
07	O
)	O

1	O
.	O
59	O
(	O
0	O
.	O
3	O
)**	O

P	O
<	O
0	O
.	O
01	O


3	O
-	O
HK	O

0	O
.	O
14	O
(	O
0	O
.	O
02	O
)	O

0	O
.	O
24	O
(	O
0	O
.	O
02	O
)**	O

P	O
<	O
0	O
.	O
01	O


3	O
-	O
HAA	O

n	O
.	O
d	O
.	O

n	O
.	O
d	O
.	O

n	O
/	O
a	O


KA	O

0	O
.	O
20	O
(	O
0	O
.	O
04	O
)	O

0	O
.	O
78	O
(	O
0	O
.	O
2	O
)**	O

P	O
<	O
0	O
.	O
01	O


XA	O

0	O
.	O
0073	O
(	O
0	O
.	O
002	O
)	O

0	O
.	O
016	O
(	O
0	O
.	O
002	O
)*	O

P	O
<	O
0	O
.	O
05	O

Metabolite	O
(%	O
saline	O
)	O

Brain	O
region	O

ANOVA	O
,	O
P	O
-	O
value	O


Dorsal	O
hippocampus	O

Ventral	O
hippocampus	O

Central	O
amygdala	O

Nucleus	O
accumbens	O


Tryptophan	O

126	O
.	O
14	O
(	O
4	O
.	O
2	O
)	O

128	O
.	O
78	O
(	O
10	O
.	O
1	O
)	O

183	O
.	O
33	O
(	O
15	O
.	O
1	O
)	O

148	O
.	O
33	O
(	O
18	O
.	O
0	O
)	O

P	O
<	O
0	O
.	O
01	O

Kynurenine	O

259	O
.	O
03	O
(	O
19	O
.	O
8	O
)	O

254	O
.	O
37	O
(	O
14	O
.	O
6	O
)	O

344	O
.	O
91	O
(	O
26	O
.	O
7	O
)	O

356	O
.	O
87	O
(	O
70	O
.	O
5	O
)	O

n	O
.	O
s	O
.	O

3	O
-	O
HK	O

146	O
.	O
92	O
(	O
16	O
.	O
5	O
)	O

127	O
.	O
98	O
(	O
14	O
.	O
7	O
)	O

170	O
.	O
49	O
(	O
25	O
.	O
2	O
)	O

169	O
.	O
22	O
(	O
15	O
.	O
0	O
)	O

n	O
.	O
s	O
.	O

3	O
-	O
HAA	O

137	O
.	O
72	O
(	O
11	O
.	O
1	O
)	O

99	O
.	O
30	O
(	O
12	O
.	O
6	O
)	O

n	O
.	O
d	O
.	O

n	O
.	O
d	O
.	O

P	O
<	O
0	O
.	O
05	O

KA	O

133	O
.	O
54	O
(	O
20	O
.	O
1	O
)	O

109	O
.	O
07	O
(	O
25	O
.	O
9	O
)	O

323	O
.	O
49	O
(	O
110	O
.	O
3	O
)	O

391	O
.	O
40	O
(	O
93	O
.	O
6	O
)	O

P	O
<	O
0	O
.	O
01	O

XA	O

268	O
.	O
78	O
(	O
37	O
.	O
2	O
)	O

201	O
.	O
84	O
(	O
28	O
.	O
4	O
)	O

200	O
.	O
66	O
(	O
29	O
.	O
0	O
)	O

224	O
.	O
32	O
(	O
38	O
.	O
5	O
)	O

n	O
.	O
s	O
.	O

